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ABSTRACT 
Ricky Camplain: Non-Hospitalized Heart Failure in the Community: Characteristics of Self-Reported and 
Outpatient Heart Failure 
(Under the direction of Gerardo Heiss) 
Heart failure (HF) is a clinical syndrome defined by combinations of signs and symptoms. It is 
associated with impaired quality of life, severe disability, and risk of death. Due to its high prevalence and 
the frequency of associated hospitalizations, HF is the leading hospital discharge diagnosis among 
Medicare patients.  
This doctoral research addressed the agreement of self-reported HF with confirmation of HF by 
the interviewee’s health care provider, hospital medical record extraction, and the presence of HF 
diagnosis codes in administrative claims. Trends in period prevalence and incidence rates of HF seen in 
emergency departments and ambulatory care clinics from 2007 to 2014 were also estimated in a national 
probability sample of Medicare beneficiaries. 
Compared to objectively measured HF among ARIC study participants, sensitivity of self-report 
was low (28-38%), specificity was high (96-97%), and agreement was poor (kappa 0.32-0.39). The 
prevalence of HF was similar whether measured by either self-report (9.0%), classification of HF 
hospitalizations (11.2%), or administrative claims for HF (12.7%).  
Among CMS Medicare fee-for-service beneficiaries, the period prevalence and incidence of HF 
in emergency departments were higher among black and older beneficiaries. The period prevalence of HF 
in emergency departments was stable from 2007 to 2014. During the same period, the incidence of HF in 
emergency departments increased among all Medicare fee-for-service beneficiaries.  
The period prevalence and incidence of HF seen in ambulatory clinics were higher among men, 
black, and older beneficiaries. The period prevalence decreased from 2007 to 2014. The incidence of HF 
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seen in ambulatory clinics decreased from 2008 to 2012, increased from 2012 to 2013, and finally 
decreased slightly in 2014 among all subgroups.  
We conclude that accurate estimates of the burden of HF in populations require that patient-
centered self-reports of HF be confirmed against sources such as diagnostic tests or medical records. 
Further, the incidence of HF seen in emergency departments and ambulatory clinics increased from 2008 
to 2014 among Medicare beneficiaries. Trends are temporally aligned with the decline of HF 
hospitalizations in the United States. These diverging temporal trends in HF may reflect the effect of 
policies designed to reduce hospitalizations for HF.  
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CHAPTER 1: INTRODUCTION 
Heart failure is a clinical syndrome resulting from cardiac disorders that impair the ventricle’s 
ability to fill with or eject blood [5]. As a result of impairment to the pumping function of the left 
ventricle of the heart, blood flow from the left ventricle into the aorta and to the peripheral arterial 
circulation is reduced. The heart is then unable to provide sufficient blood flow to meet metabolic 
requirements or accommodate systemic venous return [6]. Additionally, failure to eject the blood from the 
left ventricle leads to increased back-pressure in the pulmonary circulation, with reduced blood flow 
through the lungs and exudation (seepage of fluid) from the blood to the tissue space in the lung, 
exacerbating the accompanying impairment of respiratory function [7]. These functional impairments 
cause severe signs and symptoms (including edema, fatigue, and dyspnea) causing patients’ ability to go 
about daily living severely diminished.  
In addition to decreases in health and wellbeing, heart failure imposes a large economic burden 
on patients, their families, and the healthcare system. The estimated cost of heart failure in the United 
States (US) is $32 billion each year [8] and is predicted to increase by 127% to $69.7 billion by 2030 [4]. 
High rates of hospitalizations and hospital readmissions contribute to the burdensome cost of heart failure 
in the US. Due to the high prevalence of the disease and the frequent hospitalizations of patients, heart 
failure is the leading hospital discharge diagnosis among Medicare patients with an increase of 155% over 
the past 20 years [9].  
In response to the increasing number of hospitalizations and rehospitalizations for heart failure, 
the Centers for Medicare and Medicaid Services (CMS) initiated public reporting of hospital readmission 
rates in 2009 to encourage improvements in care. CMS will reduce payments for a hospital readmission 
for heart failure at hospitals with high hospital readmission rates [10]. This incentive is driving hospital 
systems to seek solutions that will decrease heart failure hospitalization readmission rates. Thus, efforts 
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have focused on hospitalized heart failure patients who are in the later stages of heart failure (Stage D, 
Classifications III and IV) and prevention of hospital readmission and mortality [11-25]. However, 
management of heart failure takes place largely in the outpatient setting [26, 27] and is important to 
consider when attempting to improve outcomes for patients with heart failure [28]. 
Such potential strategies to reduce heart failure hospitalizations and rehospitalizations include 
sufficient heart failure treatment in the emergency department (ED) to prevent admission to the hospital, 
as well as effective management of patients presenting with early indications of heart failure in the 
ambulatory clinic setting [26, 27]. With increased access to treatment and diagnostic tools in the ED and 
clinic, patients with heart failure may be effectively treated without admission to a hospital in order to 
reduce heart failure related hospitalizations and related costs [29-35].  
The increasing efforts to reduce rehospitalizations for heart failure highlight the need to 
understand the magnitude and temporal trends of care for heart failure in outpatient facilities to 
complement the information on burden and temporal trends of hospitalizations associated with heart 
failure diagnoses [36].  Thus, one objective of this study was to quantify the magnitude and trends in 
period prevalence and incidence rates of heart failure seen in emergency departments and ambulatory care 
clinics from 2007 to 2014 in a national probability sample of Medicare beneficiaries.  
Although estimating trends in heart failure is imperative, diagnosing and identifying heart failure 
in population research is difficult. Patient report of having physician-diagnosed heart failure has been 
used clinically and to quantify the burden of heart failure in the community. In the National Health and 
Nutrition Examination Survey (NHANES), self-report of a physician diagnosis of heart failure is used to 
estimate the prevalence of heart failure in the US. Although this difficulty is not limited to estimating the 
accuracy of self-reported heart failure, estimates comparing self-reported heart failure to clinically 
diagnosed heart failure [37], medical records [38-44], and health administrative data [40, 45] may be 
affected. Given the complexity of diagnosing and classifying heart failure, it may be difficult for health 
professionals to accurately inform patients of this diagnosis, which may limit the accuracy of self-report 
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of a physician-diagnosed heart failure and thus the practical advantage in using self-report to estimate 
prevalence of heart failure.  
Compared to self-reports of heart failure, self-reports of coronary heart disease and myocardial 
infarction have greater validity. However, most studies compared self-reported heart failure only to a 
single benchmark. Since no consensus exists on a single heart failure classification scheme, examination 
of the agreement and validity of self-reported heart failure against different benchmark definitions of 
heart failure is desirable. Thus, in the Atherosclerosis Risk in Communities (ARIC) study cohort, we 
addressed an individual’s ability to convey prior diagnoses of heart failure by estimating the agreement of 
self-reported heart failure with confirmation of heart failure by the interviewee’s health care provider, 
hospital medical record extraction, and the presence of heart failure International Classification of 
Disease, 9th Edition Clinical Modification (ICD-9-CM) codes in administrative claims. Prevalence 
estimates of heart failure based on these methods of ascertainment were compared.  
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CHAPTER 2: STUDY OBJECTIVES AND SPECIFIC AIMS 
In the proposed study, the aims are to estimate and compare agreement and prevalence of self-
reported heart failure heart failure with objective measures of heart failure as well as estimate yearly 
period prevalence and incidence rates of outpatient heart failure among Medicare fee-for-service 
beneficiaries ages 65 years and older.  
Specific Aim 1: Estimate and compare agreement of self-reported heart failure in the course of 
periodic telephone interviews with confirmation of heart failure by the interviewee’s health care provider, 
hospital medical record extraction, and the presence of heart failure International Classification of 
Disease, 9th Edition Clinical Modification (ICD-9-CM) codes in administrative claims (Manuscript 1; 
Chapter 5). 
Sub-Aim 1.1: Estimate and compare prevalence of heart failure based on self-report, hospital 
medical records, and the presence of heart failure ICD-9-CM codes in administrative claims.  
Specific Aim 2: Estimate yearly period prevalence and incidence rates of outpatient heart failure among 
CMS Medicare fee-for-service beneficiaries from 2007-2014 (Manuscript 2; Chapter 6).  
Estimating the burden of outpatient heart failure represents a critical gap in the literature needed 
to improve heart failure outcomes and reduce heart failure cost of care. Thus, among a random 20% 
sample of CMS Medicare fee-for-service beneficiaries enrolled in Parts A, B, and D, we will estimate 
yearly period prevalence as well as incidence rates of outpatient heart failure. Outpatient visits include 
emergency department visits that do not end in a hospitalization, observation stays, and clinic visits.  
The complexity of heart failure and the lack of a consensus-based definition have constrained 
assessments of the societal impact of heart failure. To date, the burden of hospitalized heart failure has 
been well described but heart failure in the outpatient setting is less well characterized.  
5 
Consideration of outpatient heart failure in the total burden of heart failure will provide novel information 
on the natural course of the syndrome as diagnosed in outpatient care and contribute new knowledge 
toward the epidemiology of heart failure and its contemporaneous impact on health care. 
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CHAPTER 3: BACKGROUND AND SIGNIFICANCE 
3.1 Pathophysiology of Heart Failure 
Heart failure (HF) is a complex clinical syndrome that results from structural or functional 
cardiac disorders that impair the ability of the ventricle to fill with or eject blood [5]. As a result of 
impairment to the pumping function of the left ventricle of the heart, blood flow from the left ventricle 
into the aorta and to the peripheral arterial circulation is reduced. The heart is then unable to provide 
sufficient blood flow to meet metabolic requirements or accommodate systemic venous return [6]. 
Additionally, failure to eject the blood from the left ventricle leads to increased back-pressure in the 
pulmonary circulation, with reduced blood flow through the lungs and exudation (seepage of fluid) from 
the blood to the tissue space in the lung, exacerbating the accompanying impairment of respiratory 
function [7].  
HF results from injury to the myocardium from a variety of causes including coronary artery 
disease, hypertension, and diabetes [6]. Less common etiologies include cardiomyopathies, valvular 
disease, myocarditis, infections, systemic toxins, and cardiotoxic drugs. Cumulative stress to the 
myocardium eventually leads to systolic or diastolic dysfunction causing clinical HF.   
There are several compensatory mechanisms that occur as the failing heart attempts to maintain 
adequate function. These include increasing cardiac output via the Frank-Starling mechanism [46], 
increasing ventricular volume and wall thickness through ventricular remodeling [47], and maintaining 
tissue perfusion with augmented mean arterial pressure through activation of neurohormonal systems [6]. 
Although initially beneficial in early stages of HF, all compensatory mechanisms eventually lead to a 
cycle of worsening HF [6].  
As the heart fails, individuals develop symptoms and signs that include dyspnea from pulmonary 
congestion, peripheral edema and ascites from impaired venous return and alterations in clinical volume 
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status (overload), and fatigue from diversion of blood away from the muscles in the limbs and the 
inefficiency of removing waste products from the body. Thus, HF is defined as a clinical syndrome that is 
characterized by specific symptoms (dyspnea and fatigue) in the medical history and signs (edema, rales) 
on the physical examination [5]. Because HF is mostly characterized by signs and symptoms, there is no 
single diagnostic test or biomarker that can serve to identify HF. HF is thus largely a clinical diagnosis 
based on a careful history and physical examination, aided by imaging and biomarkers. The progressive 
nature of this syndrome, lack of clear diagnostic criteria or screening tool, and the heterogeneous nature 
of its root causes make HF a challenging diagnostic and management problem for medical practitioners 
and researchers alike.  
3.1.1 Typology of Heart Failure 
HF can be characterized as left or right sided HF [5]. In left sided HF or left ventricular 
dysfunction, the left ventricle, does not work effectively to pump blood. Systolic HF or HF with impaired 
ejection fraction (EF) occurs when the left ventricle loses its ability to contract normally and the heart 
cannot pump blood into circulation effectively. Diastolic HF (HF with normal ejection fraction), occurs 
when the left ventricle loses its ability to relax due to stiffening of the muscles and does not fill with 
blood properly. Patients with diastolic HF present with HF-related signs and symptoms in the presence of 
a normal EF [48, 49]. Causes of diastolic HF include a decrease in passive myocardial diastolic 
compliance or impairment in active left ventricular relaxation [50]. Although patients are categorized as 
systolic or diastolic HF, most patients with systolic dysfunction also have a component of diastolic 
dysfunction [6].  
Right-sided HF, or right ventricular dysfunction, frequently occurs as a result of left-sided failure. 
As the left ventricle fails, increased fluid pressure is transferred back through the lungs, ultimately 
damaging the heart’s right side. The damage to the right side of the heart causes impaired venous return 
leading to peripheral edema and ascites. Impaired venous return also leads to increased pressure in the 
liver and the gastrointestinal tract [6].  
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3.2 Manifestations of Heart Failure 
HF is characterized by the development of signs and symptoms indicative of ventricular 
dysfunction and the presence of functional biomarkers suggestive of cardiac remodeling. The clinical 
syndrome of HF can thus be diagnosed and systematized for classification purposes according to 
symptoms in the medical history, signs on physical examinations, and clinical tests. However, there is no 
consensus on the combination of signs and symptoms indicative of HF, thus resulting in competing HF 
classification schema used in clinical research, population based studies, and in research on the impact of 
HF on healthcare.  
3.2.1 Classification of Heart Failure 
Due to the nature of HF as a symptomatic disorder, HF is typically classified according to the 
severity of symptoms experienced by a patient. The New York Heart Association (NYHA) Functional 
Classification of HF places patients in one of four categories based on how much they are limited during 
physical activity (Table 1) [5].  
Patients with a low EF may be asymptomatic, and while many patients with preserved left 
ventricular EF (LVEF) are asymptomatic, severe disability may occur. The discordance between EF and 
the degree of functional impairment is not well understood but may be explained in part by alterations in 
ventricular distensibility, valvular regurgitation, pericardial restraint, cardiac rhythm, conduction 
abnormalities, and right ventricular function [51]. Non-cardiac factors may contribute substantially to 
exercise intolerance including peripheral vascular function, skeletal muscle physiology, pulmonary 
dynamics, neurohormonal and reflex autonomic activity and renal sodium handling [5].   
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Table 1. New York Heart Association functional classification of heart failure 
Class Patient Symptoms 
I 
No limitation of physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea (shortness of breath). 
II 
Slight limitation of physical activity. Comfortable at rest. Ordinary physical 
activity results in fatigue, palpitation, or dyspnea. 
III 
Marked limitation of physical activity. Comfortable at rest. Less than ordinary 
activity causes fatigue, palpitation, or dyspnea.  
IV 
Unable to carry on any physical activity without discomfort. Symptoms of heart 
failure at rest. If any physical activity is undertaken, discomfort increases. 
 
3.2.2 Stages of Heart Failure 
HF begins with some injury to, or cumulative stress on, the myocardium and is typically 
progressive. Such progression is characterized by a change in the structure of the left ventricle, such that 
the chamber dilates and/or hypertrophies and becomes more spherical (cardiac remodeling). The change 
in structure causes hemodynamic stresses on the walls of the failing heart and may also increase 
regurgitant flow through the mitral valve. This cardiac remodeling usually precedes symptoms, continues 
after symptoms are recognized, and contributes to the worsening of symptoms, even with treatment [5].  
The development of HF described above can be characterized by four stages (Figures 1 and 2). 
The American College of Cardiology (ACC) and the American Heart Association (AHA) stages of HF 
recognize that HF has established risk factors and structural prerequisites and the development of HF has 
asymptomatic and symptomatic phases.   
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Figure 1. Stages in the development of HF and recommended therapy by stage; adapted from 
Francis et al., 1988  [1]  
 
Figure 2. American College of Cardiology – American Heart Association stage and New York 
Heart Association classification of heart failure; adapted from Farrell et al., 2002 [2] 
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The prognostic implications differ by HF stage and functional classification. HF stages are 
associated with progressively worsening 5-year survival rates [52]. Stage A and stage B (both 
asymptomatic) have 5-year survival rates above 95%. However, those who advance to stage C or D have 
a survival rate of 60% and 20%, respectively. Compared to those without HF, patients at symptomatic HF 
stages (C and D) are at severely increased risk of 10-year all-cause mortality compared to those without 
clinically diagnosed HF (hazard ratio, HR = 8.7, 31.5 respectively). However, patients without symptoms 
in stages A and B are still at an increased risk of all-cause mortality compared to those without HF. Thus, 
a patient presenting with HF-related symptoms have poorer prognosis compared to those without 
symptoms, independent of the presence of structural damage.  
3.2.3 Diagnosis of Heart Failure 
A diagnosis of HF is typically based on reported signs and symptoms, a physical exam, and 
functional test results.  
3.2.3.1 Heart Failure Related Signs and Symptoms 
Signs and symptoms of HF are due, in part, to compensatory mechanisms to adjust for a primary 
deficit in cardiac output. The major symptoms of HF are dyspnea and fatigue, particularly during 
exercise. Although major symptoms of HF are mostly present during exercise, dyspnea and fatigue 
occurring at rest and when they lay flat are indicative of severe HF.   
Dyspnea, or shortness of breath, is defined as an uncomfortable awareness of breathing [53]. 
Dyspnea is one of the most common symptoms of HF and frequently appears early in disease progression. 
Dyspnea results from an increase of pressure in the pulmonary capillary bed due to ineffective forward 
flow from the left ventricle [6]. Because dyspnea is a subjective sensation, there is no accurate objective 
measurement; however, low oxygenation is used to measure shortness of breath. When diagnosing HF, 
dyspnea on exertion has high sensitivity (0.84-1.00) but low specificity (0.17-0.34). When dyspnea is a 
symptom during ED evaluation, 48% of these patients have HF [54].  
Fatigue is a common, nonspecific symptom of HF that has a major impact on daily lives of HF 
patients. Patients report fatigue as a distressing experience, characterized by tiredness, impaired 
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functioning, difficulties in concentrating, and reduced motivation [55]. Fatigue occurs as the heart cannot 
sustain enough cardiac output to meet the body’s metabolic needs [6]. The body will then conserve blood 
flow to the heart and brain. Diversion of blood away from the muscles in the limbs and the inefficiency of 
removing waste products from the body lead to a feeling of tiredness. Structural and metabolic changes of 
skeletal muscles have been observed among patients with HF. Abnormalities of skeletal muscle histology, 
mitochondria, oxidative enzyme activities, high energy phosphate handling, and a decrease of leg muscle 
volume resulting from skeletal muscle wasting have been proposed as reasons for fatigue in patients with 
HF [56].    
HF is a frequent cause of peripheral edema. Lower extremity edema, as well as ascites, occurs 
when the right ventricle is unable to accommodate systemic venous return [6]. Activation of a series of 
humoral and neurohormonal mechanisms promotes sodium and water reabsorption by the kidneys and 
expansion of the extracellular fluid. Additionally, increased venous capillary pressure and decreased 
plasma oncotic pressure promote fluid extravasation and edema [57]. Patients with lower extremity edema 
were twice as likely to be classified as having HF compared to those who did not present with edema in 
the hospital [54].  
3.2.3.2 Diagnostic Methods of Heart Failure 
A complete history and physical examination are the first steps in diagnosing HF [5]. The former 
includes questions to reveal prior or current evidence of a myocardial infarction, valvular disease, or 
congenital heart disease. Examination of the heart may suggest the presence of cardiac enlargement, 
murmurs, or a third heart sound. However, history and physical examinations may not provide 
information about the nature of the underlying cardiac abnormality. Thus, identification of the structural 
abnormality leading to HF generally requires invasive or noninvasive techniques to assist in the diagnosis 
of HF.  
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3.2.3.2.1 Brain-Type Natriuretic Peptides 
Brain-type natriuretic peptides (BNP) are a neuro-hormones secreted mainly in the cardiac 
ventricles in response to volume expansion and pressure overload [58]. B-type natriuretic peptide (BNP) 
in their active or inactive circulating forms, have been widely incorporated into clinical practice during 
the past decade [59]. N-terminal pro b-type natriuretic peptides (NT-pro BNP) are primarily secreted from 
ventricular myocardium in response to myocyte wall stress and are therefore markedly elevated in the 
acutely decompensated state [60]. Plasma levels of BNP are elevated in patients with HF regardless of 
type [49] are indicators of HF severity and are among the most powerful prognostic markers of adverse 
outcomes, such as mortality, in patients with a variety of acute and chronic cardiovascular conditions. The 
primary use of NT-pro BNP as a diagnostic test is as an aid to the diagnosis of HF when clinical 
uncertainty exists, such as in about 40% of emergency department presentations of dyspnea [61]. Thus, 
BNP or NT-pro BNP is commonly used to rule in the presence of HF in patients presenting with HF-
related signs and symptoms, particularly dyspnea [49, 62]. NT-pro BNP testing, in conjunction with 
clinical assessment, improves the overall management of patients presenting to the emergency department 
with suspected HF through the facilitation of diagnosis [63], [63-66]. Additionally, randomized trials 
have shown that the use of BNP in the primary care setting may improve accuracy of diagnosing HF by as 
much as 20% [27].  
3.2.3.2.2 Cardiac Catheterization (Coronary Angiography) 
Catheterization can define the anatomic and physiologic severity of HF and determine the 
presence or absence of associated conditions. Catheterization yields information that may be crucial in 
defining the need for cardiac surgery, as well as its timing, risks, and anticipated benefit in a given 
patient.  Catheterization is an imaging procedure that involves putting a catheter into a blood vessel in the 
arm or leg. The physician will guide the catheter into the coronary arteries with the aid of an x-ray 
machine. Left heart catheterization involves contrast dye injected through the catheter in order to 
visualized coronary arteries.  
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3.2.3.2.3 Echocardiography  
The singularly useful diagnostic test in the evaluation of HF is a comprehensive 2-dimensional 
echocardiogram coupled with Doppler flow studies to confirm clinical suspicion of HF [5]. 
Echocardiography enables measurement of the size, structure, and movement of the heart as well as the 
movement of blood through the heart such as left ventricular filling, to address three questions when HF 
is suspected: 1) Is the left ventricular EF preserved or reduced? 2) Is the structure of the left ventricle 
normal or abnormal? 3) Are there other structural abnormalities (e.g. valvular, pericardial, right 
ventricle)?  
EF, measured by echocardiography, is defined as the fraction of blood in the ventricle ejected in 
one systole. EF values are extremely important when diagnosing HF and other conditions. By convention, 
an EF <40% indicates systolic dysfunction; if EF is >40%, diastolic dysfunction is more likely. Diastolic 
HF has is classified as having an EF measure of >55%. HF with normal EF in turn, is determined by an 
echocardiogram that indicates a disturbed pattern of ventricular filling or abnormal diastolic pressure 
gradients [49]. If a patient’s EF is lower than 55%, a patient is said to have reduced EF, or systolic HF. 
Diastolic HF, or HF with preserved EF accounts for more than 50% of HF cases [67, 68].  
3.2.3.2.4 Chest X-Ray 
A chest x-ray can contribute to a diagnostic workup by showing the size of the heart and whether 
there is evidence of increased venous pressure or frank pulmonary edema in the lungs.  
3.2.3.2.5 Electrocardiogram 
Several electrocardiogram (ECG) patterns have been reported to be associated with the risk of 
HF. Among them, QT prolongation, wide spatial angle between the mean QRS and T vectors, QRS 
nondipolar voltage, ST depression in V1, and increased T wave V1 amplitude, are predictive of HF [69-
71].  
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3.2.3.2.6 Exercise/Stress Testing 
Exercise stress tests provides information about how the functional ability of the heart to respond 
to stress. This usually involves walking on a treadmill or pedaling a stationary bike at increasing levels of 
difficulty, while the ECG, heart rate and blood pressure are monitored. If a patient is not able to do 
activity, medications, may be used to mimic the stress on the heart of the exercise test.  
3.2.3.2.7 Multigated Acquisition Scan 
Multigated acquisition (MUGA) scans are nuclear scans that evaluate the pumping functions of 
the ventricles. When an ECG is used to identify an irregular pattern such as QT prolongation, a MUGA 
scan can be used to localize the portion of the heart muscle that has sustained damage and can assess the 
degree of damage. The MUGA scan also gives an accurate and reproducible measure of the EF.  
3.2.3.3 Diagnosis of Heart Failure in the Outpatient Setting 
Characterization of the HF syndrome, which draws on combinations of clinical signs, symptoms, 
and functional measurements (described above) is often urgent and requires access to clinical evaluation 
available mostly, if not exclusively, in hospitals, EDs, and cardiology clinics but less often in the 
outpatient setting. Nonetheless, outpatient diagnoses are common, and HF diagnoses may be shifting 
form the hospital and ED setting to the outpatient clinic [27, 72].  Analyses of Canadian health insurance 
data suggest that outpatient diagnoses of HF constitute close to half of incident HF diagnoses [9, 73, 74], 
yet few studies in the US have included outpatient HF in the definition of incident HF, although reports 
suggest that diagnosis of HF in the outpatient setting is made with 50-60% accuracy [75, 76]. A wider use 
of BNP in the diagnosis of HF in the outpatient setting may improve accuracy by as much as 20% [61, 63, 
77, 78]. Similarly, the use of echocardiography, considered to be the most informative HF diagnostic test, 
is limited in primary care settings [79].  
3.3 Epidemiology of Heart Failure 
Epidemiological evidence suggests that HF affected 5.7 million Americans in 2014 [4], an 
increase of prevalence from 5.1 million in 2013 [80]. In addition to decreases in health and wellbeing, HF 
imposes a large economic burden on patients, their families, and the healthcare system. The estimated 
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cost of HF in the US is $32 billion each year [8] and is predicted to increase by 127% to $69.7 billion by 
2030 [4]. High rates of hospitalizations and hospital readmissions contribute to the burdensome cost of 
HF in the US (Figure 3). Due to the high prevalence of the disease and the frequent hospitalizations of 
patients, HF is the leading hospital discharge diagnosis among Medicare patients with an increase of 
155% over the past 20 years [9]. Thus, HF is a public health and clinical priority. 
Figure 3. Distribution of costs for heart failure in the United States (2008); adapted from 
Braunschweig et al., 2011 [3] 
 
In response to the increasing prevalence of patients hospitalized for HF, the Centers for Medicare 
and Medicaid Services (CMS) initiated public reporting of hospital readmission rates to encourage 
improvements in care, by which CMS will reduce payments for a hospital readmission for HF to hospitals 
with high hospital readmission rates [81]. This incentive is driving hospital systems to seek solutions that 
will decrease HF hospitalization readmission rates. Thus, efforts have focused on hospitalized HF patients 
who are in the later stages of HF (Stage D, Classifications III and IV) and prevention of hospital 
readmission and mortality [11-25]. However, management of HF takes place largely in the outpatient 
setting [26, 27] and is important to consider when attempting to improve outcomes for patients with HF 
[28].  
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3.3.1 Classifying Heart Failure in Population Based Studies 
Due to the complex syndromic nature of HF there is no universally accepted classification of HF, 
and population based studies assessing HF are challenged by the lack of a clear consensus in it 
systematization [82, 83]. This has prompted various schema codifying HF through combinations of major 
and minor signs and symptoms, point systems, and adjudication of medical records including 
Framingham [84], Modified Boston [85], NHANES [86], Gothenburg [87], and ARIC [88] (Appendix I). 
The available classifications draw on clinical signs, symptoms, and functional measurements that require 
access to clinical evaluation that is generally available in hospitals or emergency departments, but only 
exceptionally in the outpatient setting.  
3.3.2 Prevalence of Heart Failure 
According to self-report data from NHANES 2009-2012, an estimated 5.7 million Americans 20 
years and older (2.2%) have HF with an increase in prevalence with age (Figure 4) [4]. Overall 
prevalence in the United States ranges from 1-12% [9] and estimates vary across studies largely reflecting 
differences in ascertainment and definitions of HF. Among US Medicare beneficiaries, the prevalence of 
HF increased from 9-12% between 1994 and 2003, although the rate of increase has slowed [89].   
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Figure 4. Prevalence of heart failure by sex and age (NHANES 2009-2012); adapted from 
Mozaffarian et al., 2014 [4] 
 
The prevalence of HF seems to be increasing [89-92] and is estimated to increase by 46% by 
2030 resulting in over 8 million people suffering with HF [8]. However, reported estimates stem from 
multiple diagnostic criteria such as self-report, HF hospitalizations, hospital discharge diagnosis from 
administrative databases, and standardized criteria including Framingham, Boston, European Society of 
Cardiology, and ARIC. Studies with validated classifications of HF include the Rochester Epidemiologic 
Project in Olmsted County, Minnesota, where the prevalence of HF was 2.2% [93]. The Rotterdam cohort 
was similar with a prevalence of 1% in those 55-64 years and 10% in those older than 85 years [94].   
3.3.2.1 Prevalence Estimates Including Outpatient Heart Failure 
Very few studies to date have considered outpatient HF when estimating prevalence of HF. 
Among prevalence studies of HF that include outpatient records or claims, prevalence of HF ranged from 
<1% to 10%, similar to age comparable studies conducted with the inclusion of outpatient HF [90, 95].  
A definition of HF using diagnostic codes was developed from administrative data sets from the 
Henry Ford Hospital in Detroit, MI. HF was defined as a patient who had accumulated at least two 
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outpatient encounters in one year (emergency department, urgent care, or clinic) or one hospitalization 
coded for HF [90]. There was a linear trend for an increase in the number of prevalent cases from 1989 to 
1999 with an average increase of 1.0/1,000 for women (3.7 to 14.3/1,000) and 0.9/1,000 for men (4.0 to 
14.5/1,000). Additionally, a small study found that 10% of patients from a General Medicine Clinic had 
HF based on medical records [95]. Among patients in a single-payer health-care system in Alberta, 
Canada, prevalent cases of HF identified from administrative claims from both the inpatient and 
outpatient setting increased steadily from 1,585/100,000 patient population in 1999 to 2,510/100,000 in 
2005.  
3.3.3 Incidence of Heart Failure 
It is estimated that there are 870,000 new HF cases annually in the United States and incidence 
ranges from 2 to 5 per 1,000 population [4, 96]. The incidence of HF increases after the age of 65 years. 
Among Framingham cohort members 65 years and older, the incidence of HF is almost 10/1,000 person-
years [97] and 19.3/1,000 person-years among Cardiovascular Health Study participants [98]. 
Despite increasing prevalence of HF, the majority of evidence indicates that the incidence of HF 
is stable and might even be declining [9, 89, 99-101]. It is unclear whether the reported decreases in HF 
hospital admissions and mortality rates are attributable to lower rates of incident cases, fewer 
readmissions, a shift to more outpatient care, or improved survival. In contrast, data from Kaiser 
Permanente indicate an increase in the incidence of HF and improved survival among the elderly [102].  
3.3.3.1 Incidence Estimates Including Outpatient Heart Failure 
Incident HF has, for the most part, been defined by hospital admission [27]. Reports suggest that 
only 20% of HF hospital admissions are cases of incident HF [74]. Thus, at least in Canada, the setting in 
which HF is diagnosed may be changing from the emergency department and hospitals to the outpatient 
clinic. While the proportion of HF diagnoses in the ED declined, the proportion patients diagnosed with 
incident HF in the outpatient clinic rose from 1999-2006 [73]. Although previous reports claim 
diagnosing HF in the outpatient setting is difficult, the setting in which HF is diagnosed may be changing, 
particularly from the hospital and emergency department to the outpatient clinic [27, 73]. Almost half of 
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incident cases of HF in Canada occurred in the outpatient setting from 1997-2007 [74]. However, 
incidence and prevalence reports from the American Heart Association, NHANES, ARIC, the Multi 
Ethnic Study of Atherosclerosis, the Framingham Heart Study, and other prospective cohorts commonly 
only include hospitalized HF [75, 76].  
Among a study of inpatient and outpatient medical records conducted in Olmsted County, 
Minnesota, the incidence of HF was 2.8/1,000 in 1981 and 3.0/1,000 in 1991, not significantly different 
from other studies of incidence at the time. Additionally, in a Canadian administrative database, it was 
estimated that the incidence of HF decreased from 4.5 to 3.1/1,000 persons from 1997 to 2007 [74]. When 
evaluated separately from hospitalized HF, outpatient HF incidence also seems to not decrease 
independently [73]. The age-standardized incidence decreased from 538 in 2000 to 403/100,000 
population in 2006 overall. Among those diagnosed in the hospital setting, incidence decreased by 
415/100,000 between 2000 and 2006 while the difference in outpatient HF incidence was not significantly 
different.  
3.3.4 Societal Burden of Heart Failure 
HF places a heavy and growing burden on the health-care system. At present, economically 
developed countries devote 1-2% of all health-care expenditures toward HF [103]. The estimated cost of 
HF for 2010 was $39.2 billion, which includes health-care services, medications, and lost productivity. 
However, this figure is likely underestimated because it is based on data for HF as the primary diagnosis 
or underlying cause of death and ignores secondary diagnoses. Although hospitalizations are the main 
driver of total HF costs (Figure 3), HF is the second reason for an outpatient visit in the US [104]; thus, 
ignoring outpatient costs also underestimates the total cost of HF. 
In the US, HF is the most common condition for hospital admission in people over 65 years [105] 
with over 1.1 million hospital discharges of patients with a primary diagnosis and 2.4-3.6 million with HF 
as a primary or secondary discharge of HF in 2006 [4]. Of the patients first diagnosed with HF in the 
outpatient setting in Olmsted County, 74% were hospitalized within a mean of 1.7 years [9]. Based on the 
National Hospital Discharge Summary, adjusted hospitalization rates for HF as the primary diagnosis 
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increased by 79% between 1979 and 2004 and where HF was listed anywhere on the discharge conditions 
doubled [106]. However, the growing number of hospitalizations may be due to a decline in the length of 
stay (8 days in 1980 to 5 days in 2004) or the percentage of patient discharged from hospital to home 
(71% to 57%) [106].  
HF has been reported to be second only to hypertension as a cardiovascular reason for an office 
visit and results in 12 to 15 million outpatient visits annually in the US. HF outpatients after a myocardial 
infarction (MI) incur substantial costs within the year following hospitalization with mean costs ranging 
from $9,628 to $18,476 per patient [107]. Improved outpatient follow-up in addition to avoiding 
premature hospital discharge could have a positive impact on reducing re-hospitalization rates [108, 109].  
3.3.5 Heart Failure Hospital Readmissions and Mortality  
The 30 days following discharge of a HF hospitalization is of greatest risk for HF patients [110] 
and readmission continues to be a substantial portion of the hospitalization burden of HF. Only one-third 
of patients are seen as an outpatient within 7 days of discharge and more than one-fifth are readmitted 
within 30 days [108]. Rates of readmission are 15% lower at hospitals where patients are more likely to 
be seen within 7 days of discharge. Among US Medicare fee-for-service beneficiaries, HF was the most 
common cause of readmission with 27% of patients being readmitted within 30 days [111]. Additionally, 
an increase in readmission rates from 17% to 20% was observed among patients 65 years and older 
between 1993 and 2006 [112]. 
Despite advances in therapy and management, HF remains deadly. One in eight deaths has HF 
mentioned on the death certificate [4] and mortality risk steadily increases after a new diagnosis of HF. 
Patients admitted to the hospital with HF have greater than 10% in-hospital mortality. If a patient survives 
a hospital stay, more than 50% will either die or be re-hospitalized within a year [27]. Based on the 
Framingham Heart Study and a community study in Worchester, Massachusetts, 30-day mortality is about 
10%, 1-year mortality is 20-30%, and 5 year mortality is 45-75% [100, 102].  
While the risk of hospital readmission for HF as well as mortality following HF hospitalization is 
well established, there have been few studies that assess adverse outcomes such as hospitalization and 
22 
mortality following an outpatient visit. Between 1997 and 2007, 1-year risk-adjusted mortality decreased 
from 17.7 to 16.2% among outpatients, from 27.0 to 25.2% among inpatients and outpatients, and from 
35.7 to 33.8% among inpatients only [74].  
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CHAPTER 4: METHODS 
4.1 Specific Aim 1: Accuracy of Self-Reported Heart Failure 
4.1.1 Study Population: The Atherosclerosis Risk in Communities (ARIC) Study Cohort  
The ARIC study is an ongoing prospective cohort study of cardiovascular disease and 
atherosclerosis [113]. Recruitment occurred in 1987-1989 and included 15,792 mostly Caucasian and 
African American participants aged 45-64 years from the following four US communities: Forsyth 
County, North Carolina; Jackson, Mississippi; Washington County, Maryland; and Minneapolis, 
Minnesota (Figure 5). Standardized physical examinations and interviewer-administered questionnaires 
were conducted at baseline. Follow-up clinical examinations occurred approximately 3 years apart until 
visit 4 (1996-1998). The visit 5 examination was conducted from 2011 to 2013. Participants were 
followed-up annually through telephone interviews and review of hospitalization and vital status records.  
Figure 5. Map of the four Atherosclerosis Risk in Communities Study Communities 
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4.1.1.1 The Atherosclerosis Risk in Communities Cohort Data Linked with Center for Medicare and 
Medicaid (CMS) Medicare Claims 
The ARIC cohort participants were linked with claims from the Medicare Fee-for-Service 
program from 2005-2012, which provides hospital insurance (Part A) and supplemental insurance that 
covers physician and outpatient services (Part B) to persons ages 65 years and older in the US. While 
claims are available for all residents of the four ARIC regions, fee-for-service Medicare claims are 
specifically linked to extant data for all participants of the ARIC cohort study. The ARIC participants are 
matched to CMS Medicare data on three factors: social security number, sex, and date of birth. 
Specifically, data for ARIC cohort participants were linked with the CMS claims for the years 
1991-2012 using a finder file that included participants’ social security numbers, gender, and date of 
birth. From the total number of study participants with available social security numbers (n=15,744), 238 
died before 1991 and 607 died after 1991 but before reaching the CMS Medicare eligibility age of 65 
years, leaving 14,899 eligible ARIC study participants.   
A crosswalk file was used to identify ARIC cohort participants eligible for CMS Medicare 
coverage. The crosswalk file between the ARIC study finder file and the CMS Medicare Beneficiary 
Summary file yielded 14,702 ARIC cohort IDs (98.7 % match), 13,746 of which included a perfect match 
on all three finder file variables (social security number, gender, and birthdate). There were 952 ARIC 
participants matched using the social security number and gender and 4 participants were matched on the 
social security number and birthdate.   
Information concerning ARIC study participant enrollment in fee-for-service Medicare was 
obtained from monthly indicators of enrollment in Part A, Part B, and Medicaid buy-in available from 
annual CMS Medicare Beneficiary Summary files. Continuous enrollment periods were created to 
indicate uninterrupted CMS Medicare fee-for-service coverage, defined as enrollment in CMS Medicare 
Part A and Part B as well as lack of enrollment in a Medicare Advantage (HMO) plan.  
The CMS data are provided to the ARIC study as part of the Interagency Agreement between the 
National Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services. The CMS 
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data are curated and managed on an ongoing basis by the ARIC Study Coordination Center (University of 
North Carolina at Chapel Hill).  
Medicare enrollment information was obtained from the Medicare Beneficiary Summary file. The 
MedPAR file will be used to identify hospitalized encounters and emergency department visits which 
resulted in a hospitalization. Ambulatory care encounters and emergency department visits that did not 
result in a hospitalization were identified using the Carrier and Outpatient files. Time in a skilled nursing 
facility and home visits were excluded from analyses because these encounters do not classify within 
traditional definitions of hospitalizations or of outpatient clinical care.  
4.1.1.2 Organization for Center for Medicare and Medicaid Services Data 
The CMS data are organized into various files containing pertinent health care information 
including: The Master Beneficiary Summary File, Outpatient claim file, Carrier claim file, and the 
MedPAR file. Each file is linked by a unique beneficiary identification number. A brief description of the 
contents of these files follows.  
4.1.1.3 Master Beneficiary Summary File 
The Master Beneficiary Summary File includes beneficiary demographic traits including age, 
race, gender, and date of birth. The file includes information about beneficiary enrollment in Medicare 
Parts A and B, Medicare Advantage, and Medicaid. This file contains information about beneficiary 
residence including zip, state, and county codes. Files are provided monthly and are “frozen” in March of 
each subsequent calendar year.  
4.1.1.4 Outpatient and Carrier Claim Files 
The Outpatient claim file contains claims from institutional outpatient providers including the 
outpatient department of hospitals, rural health clinics, outpatient rehabilitation centers, and other 
federally qualified health care centers. Emergency room visits that do not result in hospitalization are also 
found in the Outpatient file.  
The Carrier claim file (Part B) contains claims from non-institutional providers including 
ambulatory surgery centers, clinical laboratories, nurse practitioners, physicians, and physician assistants.  
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4.1.1.5 The Medicare Provider Analysis and Review (MedPAR) File 
The MedPAR File contains records for inpatient hospital stays and skilled nursing facility visits. 
Emergency room visits that result in a hospitalization are identified in the MedPAR file.  
4.1.2 Heart Failure Ascertainment 
 We identified HF from self-reports and the objectively measured including physician confirmed 
HF, acute decompensated HF (ADHF) and chronic stable HF (CSHF) hospitalizations per ARIC HF 
surveillance, and HF hospitalizations and outpatient visits per CMS Medicare administrative claims.  
4.1.2.1 Self-Reported Heart Failure 
Starting in 2005, ARIC participants were asked questions regarding their HF status during annual 
follow-up phone interviews.  
In 2005, participants were asked: 
1. In a previous ARIC phone call you indicated that you had been diagnosed with heart failure or 
congestive heart failure. Do you recall you had such a diagnosis of heart failure? 
a. Was this within 3 years of the day of the interview? 
b. Were you hospitalized for heart failure at that time? 
2. Has a doctor ever said that your heart is weak or does not pump as strongly as it should, or that you 
had fluid on the lungs? 
a. Was this within 3 years of the day of the interview? 
b. Were you hospitalized for a weak heart muscle at the time? 
ARIC participants will be classified as having prevalent HF if they answer “yes” to either question 1 or 2 
above. 
In subsequent years, participants were asked: 
3. Since we last contacted you, has a doctor said that you had heart failure or congestive heart failure? 
a. What was the approximate date? 
b. Were you hospitalized for heart failure at that time? 
If negated, participants were asked:  
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4. Since we last contacted you, has a doctor said that your heart is weak or does not pump as strongly as 
it should or that you had fluid on the lungs? 
a. What was the approximate date? 
b. Were you hospitalized for the weak heart muscle at that time? 
Participants who reported a diagnosis of HF or who reported their heart was weak, their heart did 
not pump as strongly as it should, or that they had fluid in their lungs prior to 2005 were classified as 
having prevalent HF. Among remaining participants, the approximate date of diagnosis and whether or 
not the participant reported a HF-related hospitalization was also collected. Participants were classified as 
having new self-reported HF if they answered “yes” to any of the above questions.  
4.1.2.2 Physician Confirmed Heart Failure 
In parallel with assessing HF status among ARIC participants using self-reported methods, 
confirmation of HF from a physician was sought. If a participant self-reported HF or a weak heart, they 
were asked to authorize release of medical information from their physician:  
The ARIC study would like to ask your physician to tell us more about your health. If you agree 
to do this, we will send you a form that tells your physician that you authorize the ARIC study to get this 
information from your doctor. Once you sign that form and mail it back to me, we will contact your 
physician’s office. 
If a participant gave permission to contact their physician, their providers of medical care were 
sent a survey to confirm their patient’s HF status, HF characteristics, and treatment status: 
1. Has this patient ever had heart failure or cardiomyopathy of any type? 
2. Is this patient’s condition characterized as predominantly: 
a. Systolic dysfunction 
b. Diastolic dysfunction 
c. Mixed 
d. Not Determined 
3. Estimate left ventricular ejection fraction. 
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4. Estimate date of onset or diagnosis 
5. Has the patient ever had: 
a. Atrial fibrillation on an ECG? 
b. Angina pectoris? 
c. Pulmonary rales on a physical examination? 
d. Previous MI? 
e. Rhonchi on a physical examination? 
f. Other coronary heart disease? 
g. None of the above? 
6. Was this patient prescribed any of the following during the past year? 
a. ACE inhibitors 
b. Aldosterone blocker 
c. Alpha blocker 
d. Amiodarone/Antiarrhythmics 
e. Angiotensin II receptor blockers 
f. Anticoagulants 
g. Aspirin 
h. Beta blocker 
i. Calcium channel blockers 
j. Digitalis 
k. Hydralazine 
l. Lipid-lowering agents 
m. Nitrates 
n. Other anti-hypertensives   
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If a medical care provider responded “yes” to question 1 (Has this patient ever had heart failure or 
cardiomyopathy of any type?), the ARIC participant was classified as having physician confirmed HF. 
Otherwise, a participant was classified as not having physician confirmed HF.   
4.1.2.3 Heart Failure Classified by the Atherosclerosis Risk in Communities Study 
Starting in 2005, the ARIC Study conducted continuous surveillance for hospitalized HF events 
including ADHF and CSHF among cohort participants beginning in 2005. A sample of hospitalizations 
with eligible ICD-9-CM codes in any position (428.x and non-428 codes: 398.91, 402.01, 402.11, 402.91, 
404.01, 404.03, 404.11, 404.13, 404.91, 404.93, 415.0, 416.9, 425.4, 518.4, 786.0x; Table 2) is selected 
annually.  
Table 2. Eligible ICD-9-CM codes and corresponding conditions for identification of heart failure 
in the Atherosclerosis Risk in Communities Study 
Condition ICD-9-CM code 
Heart Failure 428 
Rheumatic heart disease 398.91 
Hypertensive heart disease with congestive heart failure 402.01, 402.11, 402.91 
Hypertensive heart disease and renal failure with congestive 
heart failure 
404.01, 404.03, 404.13, 404.91, 
404.93 
Acute cor pulmonale 415.0 
Chronic pulmonary heart disease, unspecified 416.9 
Other primary cardiomyopathies 425.4 
Acute edema of lung, unspecified  518.4 
Dyspnea and respiratory abnormalities 786.0 
 
Medical records were abstracted by trained study staff adhering to a common protocol [88]. First, 
the record is reviewed for any evidence of relevant HF symptoms (i.e. new onset or worsening of 
shortness of breath, edema, paroxysmal nocturnal dyspnea, orthopnea, or hypoxia) or any mention by the 
physician of HF as the reason for the hospitalization. If the hospital record contained such confirmation, a 
second, more detailed abstraction of the medical record was completed including evidence of new onset 
of symptoms, history of HF, general medical history, physical exam signs and symptoms, diagnostic tests 
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(chest X-ray, echocardiogram, cardiac cathertization, coronary angiography, cardiac radionuclide 
ventriculogram, cardiac MRI, cardiac CT scan, stress test), biomarkers (BNP, NT pro-BNP), and 
medications. Data abstracted included required elements of four diagnostic criteria commonly used 
(Framingham, modified Boston, NHANES, Gothenburg, and ICD-9-CM coding. The inter-abstractor 
agreement rate for determining whether or not to conduct a detailed abstraction in a quality control 
sample was 99%. Each hospitalization eligible for full abstraction was independently reviewed by two 
trained and certified physicians. The reviewers were provided a report of the abstracted data and classified 
hospitalizations as definite ADHF, possible ADHF, CSHF, HF unlikely, or unclassifiable. 
Hospitalizations classified as definite or possible ADHF and CSHF were considered confirmation for HF 
for our study.  
4.1.2.4 Heart Failure Identified from Administrative Claims 
Hospitalized HF was identified from MedPAR records using ICD-9-CM code 428.x in any 
position. Outpatient HF was identified from claims with Evaluation and Management service codes for 
new and established outpatient visits, consultations, and established preventive medicine visits matched 
with date of service found in the Carrier (Part B) claims. Similar to hospitalized HF, outpatient HF events 
were identified using HF-specific ICD-9-CM codes 428.0-428.9. 
More specifically, hospitalized HF was identified from annual MedPAR records using four ICD-
9-CM code algorithm definitions: 
1. ICD-9-CM code of 428.x in the primary position 
2. ICD-9-CM code of 428.x in any position 
Outpatient HF was identified from claims with Evaluation and Management service codes for 
new and established outpatient visits found the Carrier (Part B) claims. Similar to hospitalized HF, 
outpatient HF events will be identified using HF-specific ICD-9-CM codes: 
1. One occurrence of ICD-9-CM code of 428.x 
2. Two occurrences of ICD-9-CM code of 428.x within one year of each other 
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4.1.3 Eligibility 
To assess measurement properties of self-reported HF, participants were excluded if deceased or 
lost to follow-up before January 1, 2005. Participants were also excluded if they were hospitalized with a 
HF code (defined by an ICD-9-CM discharge code of 428.x in any position) or self-reported having HF 
prior to January 1, 2005.  
To estimate and compare prevalence of self-reported HF, ARIC classified HF hospitalizations, 
and HF identified from Medicare administrative claims diagnoses of participants alive from 2005-2012, 
we constructed a cohort of participants who had information available for all methods of HF 
ascertainment. Participants were included if they responded to any telephone interview questions 
regarding HF and were continuously enrolled in Medicare fee-for-service for at least one calendar month 
from 2005-2012. No exclusions were made based on prevalent heart failure prior to 2005.  
4.1.4 Statistical Analysis 
 Specific aim 1 was designed to assess verification, validity, and agreement of self-reported HF as 
well as compare prevalence estimates of HF based on self-report and on indications of HF in the health 
records and administrative claims.  
4.1.4.1 Verification of Self-Reported Heart Failure 
 To verify self-reported HF, we calculated the proportion of self-reported HF confirmed by 
physicians (verification). Because only ARIC participants who self-reported having HF (yes) were 
followed up for physician confirmed HF (yes/no), other measures of validity were not possible using 
physician confirmation. We verified whether a participant correctly self-reported HF compared to an 
independent assessment by their medical care provider by calculating the agreement between self-
reported HF and physician confirmed HF as: 
Equation 1 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 = 𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻  
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4.1.4.2 Self-Reported Heart Failure and Prior Indications of Heart Failure 
To understand the relationship between self-reported HF and prior medical encounters related to 
HF we compared self-reported HF to: 
1. Hospitalized ADHF or CSFH identified from expert review of the medical records 
2. Hospitalized and outpatient HF identified from CMS Medicare claims 
Metrics estimated included agreement, sensitivity, specificity, positive predicted value, negative 
predicted value, and the prevalence and biased adjusted kappa (PABAK).  
Participants were classified into one of four groups (Table 3): (1) having reported HF and 
hospitalized for ADHF/CSHF; (2) having self-reported HF and not hospitalized for ADHF/CSHF; (3) 
self-reporting the absence of HF and hospitalized for ADHF/CSHF; and (4) self-reporting the absence of 
HF and not hospitalized for ADHF/CSHF. Similar classifications were used for HF identified from CMS 
Medicare claims.  
Table 3. Atherosclerosis Risk in Communities Study (ARIC) participant classification 
 ADHF or CSHF 
Self-report of HF Yes No 
Yes A (true positives) B (false positives) 
No C (false negatives) D (true negatives) 
 
Similar to equation 1, agreement was calculated as the number of correctly self-reported HF (yes 
or no) divided by all participants. 
Equation 2 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 =  𝐶𝐶𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐𝐴𝐴𝑠𝑠𝐶𝐶 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻
𝐴𝐴𝑠𝑠𝑠𝑠 𝐴𝐴𝑠𝑠𝑐𝑐𝐴𝐴𝑐𝑐𝑒𝑒𝑠𝑠𝐴𝐴 𝑟𝑟𝑎𝑎𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑟𝑟𝑎𝑎𝐴𝐴𝐴𝐴𝑠𝑠  =  𝐴𝐴 + 𝐷𝐷𝐴𝐴 + 𝐵𝐵 + 𝐶𝐶 + 𝐷𝐷 
Sensitivity, the probability of a positive self-report of HF (response of “yes”) among persons with 
HF, was calculated as:  
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Equation 3 
𝑆𝑆𝐴𝐴𝐴𝐴𝑠𝑠𝑐𝑐𝐴𝐴𝑐𝑐𝑛𝑛𝑐𝑐𝐴𝐴𝐶𝐶 =  𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻  =  𝐴𝐴𝐴𝐴 + 𝐶𝐶 
Specificity, the probability of a negative self-report of HF (response of “no”) among persons 
without HF, was calculated as: 
Equation 4 
𝑆𝑆𝑟𝑟𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐴𝐴𝐶𝐶 =  𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑎𝑎𝑠𝑠 𝐴𝐴𝑐𝑐𝐴𝐴 ℎ𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴𝐴𝐴 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑤𝑤𝑐𝑐𝐴𝐴ℎ𝑐𝑐𝑜𝑜𝐴𝐴 𝐻𝐻𝐻𝐻  =  𝐷𝐷𝐵𝐵 + 𝐷𝐷 
Positive predicted value (PPV), the probability that a person has HF given that they self-reported 
HF, was calculated as: 
Equation 5 
𝑃𝑃𝑃𝑃𝑃𝑃 =  𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻  =  𝐴𝐴𝐴𝐴 + 𝐵𝐵 
Negative predicted value (NPV), the probability that a person does not have HF given that they 
self-reported not having HF, was calculated as:  
Equation 6 
𝑁𝑁𝑃𝑃𝑃𝑃 =  𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑎𝑎𝑠𝑠 𝐴𝐴𝑐𝑐𝐴𝐴 ℎ𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴𝐴𝐴 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑎𝑎𝑠𝑠 𝐴𝐴𝑐𝑐𝐴𝐴 ℎ𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴𝐴𝐴 𝐻𝐻𝐻𝐻  =  𝐷𝐷𝐶𝐶 + 𝐷𝐷 
Because the prevalence of HF is low, chance agreement will be high and kappa can have 
unexpectedly low values. To adjust for this, and for the bias of kappa, the prevalence and biased adjusted 
kappa (PABAK) can be used [114]. PABAK was calculated as:  
Equation 7 
𝑃𝑃𝐴𝐴𝐵𝐵𝐴𝐴𝑃𝑃 =  2(𝑟𝑟𝐴𝐴𝑐𝑐𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴 𝑐𝑐𝑐𝑐 𝑎𝑎𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴) − 1 = 2( 𝐴𝐴 + 𝐷𝐷
𝐴𝐴 + 𝐵𝐵 + 𝐶𝐶 + 𝐷𝐷) 
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4.1.4.3 Estimates of Prevalence 
 Prevalence and 95% confidence intervals (CI) for self-reported HF, ARIC classified HF 
hospitalizations, and HF identified from Medicare administrative claims diagnoses were estimated and 
compared from 2005-2012. We made no attempt to align the years of HF report with HF hospitalizations 
or administrative claims, but rather took yes responses at any time as having agreed.  
4.2 Specific Aim 2: Trends in Outpatient Heart Failure 
4.2.1 Study Population: 20% Random Sample of Center for Medicare and Medicare Services Medicare 
fee-for-service Claims Data 
 The UNC Department of Epidemiology houses a sample of approximately 20 percent of all 
Medicare beneficiaries ages 65 years and older with fee-for-service coverage of Medicare Parts A, B, and 
D. Beneficiaries are included in the data set if they have simultaneous coverage of Parts A, B, and D for 
at least one calendar month in 2007-2014. Once a beneficiary meets these selection criteria, all available 
fee-for-service claims data and death data are included from that point through the end of 2014 
(http://www.shepscenter.unc.edu/data/medicare-data-20-sample/). The data are updated yearly using the 
same sampling scheme for each year. There is an approximately 24-month lag for updating (e.g., the 2011 
data were uploaded in December 2013).  
4.2.1.1 Organization of the Center for Medicare and Medicaid Services Medicare Fee-For-Service Claims 
(20% Random Sample) 
 The Medicare data are contained in a series of data files described in detail on the ResDAC 
website (http://www.resdac.org/). ResDAC, the Research Data Assistance Center, is a contractor for the 
Centers for CMS that provides free assistance to academic, government, and non-profit researchers 
interested in using Medicare and/or Medicaid data for research.  
4.2.1.2 The Beneficiary Annual Summary File 
The Beneficiary Annual Summary File contains demographic information, including county of 
residence, dates of death, and comorbidity flags that can be used to identify patients with certain chronic 
conditions.  
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4.2.1.3 The Medicare Claims File 
The Medicare Claims Files contain fully adjudicated paid claims and dates of service for all non-
capitated ambulatory, emergency department, inpatient, and outpatient encounters (including 
administrative claims for laboratory tests), skilled nursing facility, hospice, home health, and durable 
medical equipment claims for patients at the time of service. Diagnoses and procedures are identified by 
the International Statistical Classification of Diseases and Related Health Problems (ICD-9); Current 
Procedural Terminology (CPT); and Health Care Financing Administration (HCFA) Common Procedure 
Coding System (HCPCS) codes for both outpatient and inpatient visits/stays. Physician, specialist, and 
emergency room visits, as well as hospital stays, are captured in the database through CPT codes, revenue 
codes (e.g., room and board), used on billing forms such as the UB-92, and place of service codes. The 
Medicare Claims files include the following: Carrier RIF, Durable medical Equipment RIF, Home Health 
Agency RIF, Hospice RIF, Inpatient RIF, Outpatient RIF, Skilled Nursing Facility RIF, and MedPAR 
RIF.  
4.2.2 Heart Failure Ascertainment  
Outpatient HF visits were identified from Carrier and Outpatient files using claims for new and 
established office visits to primary care physicians and cardiologists, urgent care, visits to the emergency 
department that did not end in a hospital admission (routine discharge), and observation stays. Outpatient 
HF was classified by ICD-9-CM code 428.x in any position in the outpatient record.  
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4.2.2.1 Emergency Department Heart Failure Visits 
 Emergency department visits with a routine discharge and observation stays were classified as 
emergency department visits. 
4.2.2.2 Ambulatory Clinic Heart Failure Visits 
 Visits to primary care physicians and cardiologists and urgent care were classified as clinic visits.  
4.2.3 Eligibility 
To estimate yearly heart failure period-prevalence, beneficiaries were included if they had a 
medical claim and were enrolled in Medicare fee-for-service Parts A and B for at least one calendar 
month. All enrollment periods were included for beneficiaries with ≥1 enrollment period. To estimate 
incidence rates of heart failure, beneficiaries were included if they were enrolled in continuous Medicare 
fee-for-service Parts A and B for ≥2 years. If a beneficiary had ≥1 enrollment period, we included the first 
enrollment period ≥2 years.  
4.2.4 Statistical Analysis 
 Specific aim 2 is designed to estimate yearly period prevalence and incidence rates for 
beneficiaries with heart failure seen in the emergency department and clinic.  
Descriptive characteristics were expressed as number of observations and percentages. Numbers 
of beneficiaries were multiplied by five to represent the United States Medicare fee-for-service 
population. We calculated yearly trends in heart failure period prevalence and corresponding 95% CI by 
dividing the number of individuals with a heart failure event by the total number of beneficiaries enrolled 
in Medicare fee-for-service in our sample. Incidence rates per 1,000 person years and 95% CIs were 
calculated by dividing the number of incident events by the total person-time contributed by Medicare 
beneficiaries enrolled in fee-for-service. Cochran-Armitage tests for trend were used. Analyses and the 
presentation of results were stratified by age group (65-74, 75-79, 80-84, and ≥85 years), race (white, 
black, Hispanic, Asian, and Native American), and sex. Prevalence ratios and incidence rate ratios were 
estimated to determine differences between sex, age, and race groups.  
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CHAPTER 5: MANUSCRIPT #1, ACCURACY OF SELF-REPORTED HEART FAILURE. THE 
ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY 
5.1 Introduction 
Patient report of having physician-diagnosed heart failure (HF) has been used clinically and to 
quantify the burden of HF in the community. In the National Health and Nutrition Examination Survey 
(NHANES), self-report of a physician diagnosis of HF is used to estimate the prevalence of HF in the 
United States (US). HF is difficult to diagnose and identify in population research. Although this 
difficulty is not limited to estimating the accuracy of self-reported HF, estimates comparing self-reported 
HF to clinically diagnosed HF [37], medical records [38-44], and health administrative data [40, 45] may 
be affected. Given the complexity of diagnosing and classifying HF, it may be difficult for health 
professionals to accurately inform patients of this diagnosis, which may limit the accuracy of self-report 
of a physician-diagnosed HF and thus the practical advantage in using self-report to estimate prevalence 
of HF.  
Compared to self-reports of HF, self-reports of coronary heart disease and myocardial infarction 
have greater validity. However, most studies compared self-reported HF only to a single benchmark. 
Since no consensus exists on a single HF classification scheme, examination of the agreement and 
validity of self-reported HF against different benchmark definitions of HF is desirable. Thus, in the 
Atherosclerosis Risk in Communities (ARIC) study cohort, we addressed an individual’s ability to 
convey prior diagnoses of HF by estimating the agreement of self-reported HF with confirmation of HF 
by the interviewee’s health care provider, hospital medical record extraction, and the presence of HF 
International Classification of Disease, 9th Edition Clinical Modification (ICD-9-CM) codes in 
administrative claims. Estimates of the prevalence of HF based on these methods of ascertainment were 
compared.  
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5.2 Methods 
5.2.1 Study Population 
The ARIC study is an ongoing prospective cohort of 15,792 men and women aged 45-64 years at 
baseline (1987-1989) and recruited from the following four US communities: Forsyth County, North 
Carolina; Jackson, Mississippi; Washington County, Maryland; and suburban Minneapolis, Minnesota 
[113]. Standardized physical examinations and interviewer-administered questionnaires were conducted 
at baseline and at four follow-up visits through 2012. Participants were additionally followed-up annually 
(from 1987) and semi-annually (beginning in 2012) through telephone interviews and review of 
hospitalization and vital status records. Institutional Review Boards at each participating institution 
approved the study and all participants provided written informed consent at each examination.  
5.2.2 Self-Reported Heart Failure 
Starting in 2005, participants were asked questions regarding their HF status during annual 
follow-up telephone interviews. Participants who reported a diagnosis of HF or who reported that their 
heart was weak, their heart did not pump as strongly as it should, or that they had fluid in their lungs prior 
to 2005 were classified as having prevalent HF.  Remaining participants, free of self-reported HF prior to 
2005, were asked at the initial (2005) and subsequent annual telephone interviews whether a doctor said 
that they had HF since the last time they were contacted or if their heart was weak or did not pump as 
strongly as it should. The approximate date of diagnosis and whether or not the participant reported a HF-
related hospitalization was also collected. Participants were classified as having new self-reported HF if 
they answered “yes” to any of the above questions.   
5.2.3 Physician Confirmed Heart Failure 
In parallel with assessing ARIC participants’ self-reported HF status, a confirmation of HF from 
the participant’s physician was sought. If a participant reported being diagnosed with HF, or told by a 
physician that his/her heart was pumping weakly, they were asked to authorize a release of medical 
information from their physician. If a signed authorization was obtained, the provider of medical care was 
sent a survey to confirm their patient’s HF status, HF characteristics, and treatment status.   
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5.2.4 ARIC Classified Heart Failure 
Prior to 2005, ARIC recorded ICD-9-CM codes but did not abstract HF records; we excluded 
from this analysis those who had an ICD-9-CM discharge code of 428.x in any position.  Starting in 2005, 
the ARIC Study has been conducting continuous surveillance of hospitalized HF events, including acute 
decompensated HF (ADHF) and chronic stable HF (CSHF) among cohort participants. A sample of 
hospitalizations with eligible ICD-9-CM codes in any position is selected annually [88] for review. 
Medical records are abstracted by trained study staff adhering to a common protocol [88]. First, each 
record is reviewed for any evidence of relevant HF symptoms or mention by the physician of HF in the 
hospital record. If the hospital record contains such confirmation, a detailed abstraction of the medical 
record is completed. Data abstracted include required elements of four diagnostic criteria commonly used 
(Framingham, modified Boston, NHANES, Gothenburg) and ICD-9-CM coding. Each hospitalization 
eligible for full abstraction is independently reviewed by two physicians. The reviewers are provided 
relative portions of the medical record and a report of the abstracted data. Reviewers then classify 
hospitalizations as definite ADHF, possible ADHF, chronic stable HF, HF unlikely, or unclassifiable. 
Hospitalizations classified as definite or possible ADHF and chronic stable HF were considered 
confirmation of HF for our study. 
5.2.5 Heart Failure Identified from Administrative Claims 
ARIC cohort participants’ identifiers were linked with Centers for Medicare and Medicaid 
Services (CMS) Medicare claims for the years 1991-2013 using a finder file that included participants’ 
social security numbers, gender, and date of birth. From the total number of study participants with 
available social security numbers (n=15,744), 238 died before 1991 and 607 died after 1991 but before 
reaching the Medicare eligibility age of 65 years, leaving 14,899 eligible ARIC study participants. A 
crosswalk file was used to identify ARIC cohort participants eligible for Medicare coverage. The 
crosswalk file between the ARIC study finder file and the Medicare Beneficiary Summary file yielded 
14,702 ARIC cohort IDs for analyses (98.7 % match).   
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Information concerning ARIC study participant enrollment in fee-for-service (FFS) Medicare was 
obtained from monthly indicators of enrollment in Part A, Part B, and Medicaid buy-in available from 
annual Medicare Beneficiary Summary files. Continuous enrollment periods were created to indicate 
uninterrupted FFS Medicare coverage, defined as enrollment in Medicare Part A and Part B as well as 
lack of enrollment in a Medicare Advantage (HMO) plan. All inpatient and outpatient claims were linked. 
Hospitalized HF was identified from Medicare Provider Annual Review (MedPAR) records using ICD-9-
CM code 428.x in any position. Outpatient HF was identified from claims with Evaluation and 
Management service codes for new and established outpatient visits, consultations, and established 
preventive medicine visits matched with date of service found in the Carrier (Part B) claims. Similar to 
hospitalized HF, outpatient HF events were identified using HF-specific ICD-9-CM codes 428.0-428.9. 
5.2.6 Eligibility 
To assess measurement properties of self-reported HF, participants were excluded if deceased or 
lost to follow-up before January 1, 2005 (Figure 6). Participants were also excluded if they were 
hospitalized with a HF code (defined by an ICD-9-CM discharge code of 428.x in any position) or self-
reported having HF prior to January 1, 2005.  
To estimate and compare prevalence of self-reported HF, ARIC classified HF hospitalizations, 
and HF identified from Medicare administrative claims diagnoses of participants alive from 2005-2012, 
we constructed a cohort of participants who had information available for all methods of HF 
ascertainment. Participants were included if they responded to any telephone interview questions 
regarding HF and were continuously enrolled in Medicare fee-for-service for at least one calendar month 
from 2005-2012. No exclusions were made based on prevalent heart failure prior to 2005.  
5.2.7 Statistical Analysis 
To verify self-reported HF, we calculated the proportion of self-reported HF confirmed by 
physicians (verification). Because only ARIC participants who self-reported having HF (yes) were 
followed up for physician confirmed HF (yes/no), other measures of validity were not possible using 
physician confirmation (Table 4). To directly compare self-reported HF to other methods of HF 
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ascertainment, we also calculated verification for ARIC classified HF and HF ascertained from 
administrative claims.  
To compare self-reported HF (yes, no) with ARIC classified HF (yes/no) or administrative claims 
(yes/no), participants were classified as true positives, true negatives, false positives, or false negatives for 
each comparison. We evaluated agreement (the number of true positives and negatives divided by all 
participants), positive predictive value (PPV, probability that a participant has HF given that they 
positively self-reported HF), sensitivity (probability of positively self-reporting HF among participants 
with HF), and specificity (probability of negatively self-reporting HF among participants without HF) 
(Table 4). Lastly, we examined prevalence and biased adjusted kappa (PABAK) [114]. Because both 
prevalence and bias play a part in determining the magnitude of the kappa coefficient and the prevalence 
of HF is relatively low (~10%), PABAK is a more appropriate measure of agreement compared to the 
traditional kappa. PABAK is calculated as 2Io-1 where Io is the observed agreement.  
Prevalence and 95% confidence intervals (CI) for self-reported HF, ARIC classified HF 
hospitalizations, and HF identified from Medicare administrative claims diagnoses were estimated from 
2005-2012. We made no attempt to align the years of HF report with HF hospitalization or administrative 
claim, but rather took yes responses at any time as having agreed. 
All analyses were conducted using SAS V9.4 (SAS Inc. Cary, North Carolina). 
5.3 Results 
Of the 15,792 members of the ARIC cohort, 3,305 were deceased (N=2,884) or lost to follow-up 
before January 1, 2005 and 1,556 participants were classified as having prevalent HF, leaving 11,846 
participants for analysis (Figure 6). Among eligible ARIC participants, 59% were female and 25% were 
African American (Table 5) and their age range was 60-83 years in 2005. Over 40% of participants had 
hypertension and 12% had diabetes at baseline (2005). ARIC participants with Medicare fee-for-service 
coverage were similar in age, gender, racial, and comorbidity composition to all eligible ARIC 
participants. Participants who self-reported HF were older, more likely to be male and had higher 
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prevalence of diabetes, hypertension, myocardial infarction, stroke, and coronary heart disease at baseline 
(Table 5).  
5.3.1 Verification of Heart Failure 
Between January 1, 2005 and December 31, 2012, of the 765 participants who self-reported HF, 
379 (49.5%, Table 6) participants had information regarding confirmed HF status. Of those, 231 of the 
participants’ physicians confirmed their patients had HF (agreement=60.9%, 95% CI: 56.0, 65.9, Table 
7).  
5.3.2 Comparison of Self-Reported and ARIC Classified Heart Failure 
The probability that a participant had ARIC classified HF given that they positively self-reported 
HF (PPV) was 49.5% (95% CI: 45.9, 53.1, Table 7). Sensitivity comparing self-reported to ARIC 
classified HF was low (38.5%, 95% CI: 35.4, 41.6) and specificity was high (96.4%, 95% CI: 96.1). We 
verified 49.5% (95% CI: 46.0, 53.1) of participants’ self-reported HF; kappa was 0.39 (CI: 0.35, 0.42) and 
PABAK was 0.83 (95% CI: 0.82, 0.85).  
5.3.3 Comparison of Self-Reported Heart Failure and Heart Failure Identified from Administrative Claims 
Of the 11,846 eligible ARIC participants, 9,347 were enrolled in Medicare fee-for-service for at 
least one calendar month from January 1, 2005 to December 31, 2012. Among them, 45% (95% CI: 41.2, 
48.8) of the participants who self-reported HF had been hospitalized with a HF code according to 
administrative claims, and 60.9% (95% CI: 57.1, 64.6) of participants who self-reported HF had been 
hospitalized or were seen in the outpatient setting with a HF code (Table 7). Overall agreement between 
self-reported HF and hospitalized HF identified from administrative claims, measured by kappa, was 0.34 
(95% CI: 0.31, 0.37) while the agreement with HF identified from administrative hospitalization and 
outpatient claims decreased to 0.32 (95% CI: 0.29, 0.34). Similarly, the sensitivity, PPV, and PABAK 
decreased when outpatient claims were included in the comparison definition. This decrease in 
agreement, sensitivity, and PPV is partially due to the shift of participants from true negatives to false 
negatives (Table 6).  
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5.3.4 Prevalence 
Of the eligible participants enrolled in Medicare fee-for-service (N=9,886), 886 ever self-reported 
HF (9.0%, 95% CI: 8.4, 9.5), 1,105 participants’ hospitalizations were confirmed by ARIC (11.2%, 95% 
CI: 10.6, 11.8), 1,256 participants were hospitalized for HF with an ICD-9-CM code of 428.x identified 
from administrative claims (12.7%, 95% CI: 12.0, 13.4), and 1,839 participants were hospitalized or seen 
in the outpatient setting for HF identified from administrative claims (18.6%, 95% CI: 17.8, 19.4, Table 
8).   
5.4 Discussion 
Health-status questionnaires continue to be important tools in epidemiology and public health 
research. To assess the accuracy of self-reported HF compared to objective measures of HF, we evaluated 
agreement between self-reported HF with confirmation of the diagnosis of HF by the interviewee’s health 
care provider, prior indications of HF in an individual’s hospital records, and HF identified from 
administrative claims. We observed a low agreement (kappa 0.32-0.39) between HF self-reported by 
participants and objective measures of HF. Self-reports of HF were characterized by frequent false 
positives and false negatives compared with true positives. Adjustment of kappa statistics for prevalence 
and bias improved agreement to 0.73-0.83. Sensitivity was low (28-38%) and specificity was high (96-
97%) for all methods of HF ascertainment. Prevalence estimates of HF estimated ARIC classified HF 
hospitalizations and hospitalized HF ascertained from administrative claims among ARIC participants 
were comparable. However, when prevalence was lower when estimated from self-reports and higher 
when estimated from administrative claims for hospitalized and outpatient HF.  
Previous studies have compared self-reported HF to a single validation benchmark, making 
comparisons across studies difficult. Thus, our study was designed to directly compare the agreement 
between self-reported HF and objective measures of HF including in-depth medical record review, 
administrative claims, and confirmation from a physician. Among previous reports estimating the 
agreement of self-reports of physician-diagnosed HF and medical records, agreement (kappa) ranged 
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from 0.30-0.48 with low to fair sensitivity (31-69%) and high specificity (0.91-0.97) [38-44]. Our study 
yielded similar results with low sensitivity (39%) and agreement (0.32-0.39) and high specificity (96%).  
A study by Baumeister et al. compared self-reported HF with physical examinations and lab data [37]. 
That study’s agreement (kappa=0.74) and sensitivity (89%) were higher compared to other studies [38-
44].  Although we do not have a direct comparison to the Baumeister et al. study, our validation results 
were highest for self-reported HF compared to physician confirmed HF (61%). Although physician 
confirmed HF is thought to be the closest to a gold standard, as contrasted with ARIC classified HF and 
administrative claims, only 379 participants were included in our analysis of physician confirmed HF. We 
sought physician confirmation only from participants who self-reported that a physician had told them 
they had HF. Only 49.5% of physicians ultimately returned the HF survey to ARIC, although 
characteristics of participants with physician confirmation were not fundamentally different from those 
for whom we did not receive a physician confirmation form (data not shown).  
Similar to medical record review, studies comparing self-report to HF identified from hospital 
administrative claims returned low agreement (0.19-0.33) and sensitivity (26%) and high specificity 
(99%) [40, 45]. Among ARIC participants with CMS Medicare fee-for-service, sensitivity (28-35%), 
specificity (96-97%), and agreement (0.32-0.34) were comparable. Although our results can be compared 
to other studies, administrative data have high variation in validity for recording HF [115] and significant 
differences exist in the manner in which hospitalizations are recorded in administrative claims compared 
with medical records [116, 117]. Although there are significant differences, identification of hospitalized 
patients with HF by means of Medicare diagnostic codes are similar to that based on diagnostic codes 
available from medical records, but low sensitivity may limit the accurate identification of HF events 
solely on the basis of Medicare diagnostic codes.  
Previous studies indicated that self-reports of conditions characterized by complex, nonspecific 
symptoms, such as HF, have poor agreement compared with objective measures of the condition in 
contrast to conditions that are better characterized and more easily diagnosed such as myocardial 
infarction, stroke, and diabetes [38-42, 45, 118]. The low agreement of self-report with objective 
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measures of HF may be a consequence of HF being a more complex syndrome, the lack of symptom 
specificity, and its varied presentation. A lack of consensus on the combination of signs and symptoms to 
classify HF, has introduced several HF classification schema into clinical and research settings, [119], and 
contributes to a lack of common definitions of HF among health care professionals.  Clinical practitioners 
may thus have contributed some of the observed lack of agreement with self-reported HF observed in our 
data. More relevant, the chronic cardio-respiratory morbidity that characterized many of the study 
participants who self-reported HF likely contributed to the lack of agreement with the practitioners’ 
diagnoses: among the 148 participants whose physicians reported their patients did not have HF although 
their patients self-reported HF, physicians reported that 103 (69.6%) ever had atrial fibrillation, angina 
pectoris (n=37), a previous MI (n=20),, or another coronary heart disease (n=60). Conditions such as 
these may have led to self-reports of  a “weak heart”.  
In comparing self-reported and objectively measured HF, all our agreement measures were 
influenced by the low prevalence of HF (<10%). Kappa coefficients may be decomposed into components 
reflecting observed agreement, bias, and prevalence. When comparisons are made between agreement 
studies, it can be misleading to report kappa values alone, and it is recommended that researchers discuss 
the effects of bias and prevalence. No studies to our knowledge have used the PABAK to estimate the 
agreement of self-reported HF with objective measures of HF. Although our kappa estimates were low, 
our PABAK estimates were much higher (0.73-0.83). While PABAK hypothetically adjusts for 
prevalence, PABAK may overestimate the agreement between our data sources.  Some are critical of the 
use of PABAK because the effects of reporting bias and prevalence on the magnitude of kappa are 
themselves informative and should not be adjusted for [120]. Although no single agreement statistic can 
fully capture the desired information, when presented in addition to a value of kappa the PABAK gives an 
indication of the likely effects of prevalence and bias alongside the value of kappa [121].  
In addition to describing the agreement of self-report with objective measures of HF, we present a 
comparison of estimated HF prevalence based on different ascertainment methods in the same population. 
Although prevalence estimates for ARIC classified HF hospitalizations (11.2%) and hospitalized HF 
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identified from administrative claims (12.7%) were similar, only 824 participants were identified in both 
prevalence estimates (Table 9). Furthermore, only 396 (4.0%) participants self-reported HF, were 
identified by ARIC adjudication of medical records, and had a HF hospitalization identified from 
administrative claims.  
As hypothesized, including outpatient claims in the definition of HF ascertained from 
administrative claims substantially increased the prevalence of HF in this population. Although 
approximately half the HF patients are managed in the outpatient setting (without a hospitalization) and 
HF patients are increasingly diagnosed and treated in outpatient clinics [73, 74], population estimates of 
HF rarely include outpatient HF. These trends in medical care, coupled with the comparison of prevalence 
estimates above, underscore the importance of stating clearly the definition of HF when presenting 
frequency estimates.  
5.5 Conclusion 
Our results suggest that agreement of self-reported HF with physician confirmed HF, prior 
indications of HF in the patient’s health record, and HF identified from administrative claims is low to 
fair and self-reported HF is insensitive. Further, population estimates of self-reported HF are comparable 
to those from hospitalizations with HF discharge diagnoses, but the identification of “cases” of HF is not 
accurate.  For accurate population estimates of HF, self-reported HF data should be coupled with other 
sources such as diagnostic tests or medical records.  
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Figure 6. Study design, The Atherosclerosis Risk in Communities (ARIC) Study (2005-2012) 
 
Abbreviations: Heart failure (HF), Fee-for-service (FFS) 
a Definite and probable acute decompensated heart failure and chronic stable heart failure ascertained from reviewed abstracted medical records 
b Ascertained from heart failure surveys sent to participant’s physicians for confirmation of heart failure diagnosis 
c Centers for Medicare and Medicaid Services Medicare claims, International Classification of Disease, 9th Edition Clinical Modification (ICD-9-CM) code 428.x 
in any position present in the hospital record, ICD-9-CM 428.x in any position present in the hospital record or ICD-9-CM 428.x present in the outpatient record 
Self-reported heart failure ascertained from ARIC annual follow up telephone interviews
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Table 4. Agreement estimates of self-reported heart failure vs. objective measures of heart failure, 
The Atherosclerosis Risk in Communities (ARIC) Study 
 Physician Confirmed 
Heart Failure 
ARIC Classified  
Heart Failure a 
Heart Failure Identified 
from Administrative 
Claims b 
Verification c    
Kappa    
PABAK    
Sensitivity    
Specificity    
PPV    
Abbreviations: Prevalence and biased adjusted kappa (PABAK); positive predicted value (PPV) 
a Definite and probable acute decompensated heart failure and chronic stable heart failure ascertained 
from reviewed abstracted medical records 
b Centers for Medicare and Medicaid Services Medicare claims 
c Confirmed heart failure among self-reporters of heart failure 
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Table 5. Descriptive characteristics by heart failure ascertainment, The Atherosclerosis Risk in 
Communities (ARIC) Study, 2005-2012 
 ARIC participants who may be classified as having heart failure 
 
Physician confirmed  
heart failure  
(N = 379) 
ARIC classified  
heart failure a 
(N = 11,846) 
Heart failure 
identified from 
administrative 
claims b 
(N = 9,347) 
 Mean (Standard Deviation)  
Age (years), mean (standard 
deviation) c 72 (5.6) 71 (5.7) 
71 (5.5) 
 N (%) 
% Female 181 (48) 6,960 (59) 5,584 (60) 
% African American 100 (26) 2,912 (25) 2,492 (27) 
Center    
Forsyth County 58 (15) 3,104 (26) 2,049 (22) 
Jackson 93 (24) 2,532 (21) 2,219 (24) 
Minneapolis 104 (27) 3,236 (27) 2,266 (24) 
Washington County 124 (33) 2,974 (25) 2,813 (30) 
Comorbidities     
Diabetes d 82 (22) 1,386 (12) 1,161 (12) 
Hypertension e 236 (62) 5,270 (44) 4,340 (46) 
Myocardial infarction f 67 (18) 551 (5) 452 (5) 
Stroke g 24 (6) 331 (3) 288 (3) 
Coronary heart disease h 90 (24) 654 (6) 536 (6) 
a Definite and probable acute decompensated heart failure and chronic stable heart failure ascertained from 
reviewed abstracted medical records 
b Centers for Medicare and Medicaid Services Medicare (CMS) fee-for-service inpatient and outpatient claims 
c Age at start of follow-up (January 1, 2005) 
d Fasting glucose ≥126, non-fasting glucose ≥200, using medication for diabetes, or self-reported diagnosis of 
diabetes at start of follow-up (January 1, 2005) 
e Systolic blood pressure ≥140, diastolic blood pressure ≥90, or on medication for high blood pressure at start of 
follow-up (January 1, 2005)  
f Incident myocardial infarction at start of follow-up (January 1, 2005) ascertained from ARIC surveillance 
g Incident stroke at start of follow-up (January 1, 2005) ascertained from ARIC surveillance 
h Prevalent coronary heart disease at start of follow-up (January 1, 2005) ascertained from ARIC surveillance  
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Table 6. Self-report of heart failure and objective measures of heart failure, The Atherosclerosis 
Risk in Communities (ARIC) Study (2005-2012) 
   Administrative claims b 
 
Physician 
confirmed 
heart failure 
(N = 379) 
ARIC classified 
heart failure a 
(N = 11,846) 
Heart failure 
hospitalizations c 
(N = 9,347) 
Heart failure 
hospitalizations 
and outpatient 
visits d 
(N = 9,347) 
 
Yes No Yes No Yes No Yes No 
Self-report of HF        
Yes 231 148 379 386 292 357 395 254 
No -- -- 606 10,475 554 8,144 996 7,702 
a Definite and probable acute decompensated heart failure and chronic stable heart failure ascertained 
from reviewed abstracted medical records 
b Centers for Medicare and Medicaid Services Medicare (CMS) fee-for-service inpatient and 
outpatient claims 
c International Classification of Disease, 9th Edition Clinical Modification (ICD-9-CM) code 428.x in 
any position present in the hospital record 
d ICD-9-CM 428.x in any position present in the hospital record or ICD-9-CM 428.x present in the 
outpatient record 
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Table 7. Agreement between self-report of heart failure and objective measures of heart failure, The Atherosclerosis Risk in Communities 
(ARIC) Study, 2005-2012 
     Administrative claims b 
 
Physician confirmed 
heart failure 
(N = 379) 
 
ARIC classified 
 heart failure a 
(N = 11,846) 
 
Heart failure 
hospitalizations c 
(N = 9,347) 
 
Heart failure 
hospitalizations and 
outpatient visits d 
(N = 9,347) 
 % (95% CI)  % (95% CI)  % (95% CI)  % (95% CI) 
Verification e 60.9 (56.0, 65.9)  49.5 (46.0, 53.1)  45.0 (41.1, 48.8)  60.9 (57.1, 64.6) 
Sensitivity --  38.5 (35.4, 41.6)  34.5 (31.3, 37.8)  28.4 (26.1, 30.9) 
Specificity  --  96.4 (96.1, 96.8)  95.8 (95.3, 96.2)  96.8 (96.4, 97.2) 
Positive Predicted Value --  49.5 (45.9, 53.1)  45.0 (41.3, 48.9)  60.9 (57.0, 64.6) 
Kappa --  0.39 (0.35, 0.42)  0.34 (0.31, 0.37)  0.32 (0.29, 0.35) 
PABAK --  0.83 (0.82, 0.85)  0.81 (0.79, 0.82)  0.73 (0.71, 0.75) 
Abbreviations: Prevalence and biases adjusted kappa (PABAK) 
Confirmed heart failure: Physician confirmed heart failure N = 231; ARIC classified heart failure N = 379; hospitalized heart failure identified 
from administrative claims N = 292; hospitalized and outpatient heart failure identified from administrative claims N = 395 
Prevalence: Self-reported heart failure (6.9%); ARIC classified heart failure (8.8%); hospitalized heart failure identified from administrative 
claims (9.1%); hospitalized and outpatient heart failure identified from administrative claims (14.9%) 
a Definite and probable acute decompensated heart failure and chronic stable heart failure ascertained from reviewed abstracted medical records 
b Centers for Medicare and Medicaid Services Medicare claims 
c International Classification of Disease, 9th Edition Clinical Modification (ICD-9-CM) code 428.x in any position present in the hospital record 
d ICD-9-CM 428.x in any position present in the hospital record or ICD-9-CM 428.x present in the outpatient record 
e Confirmed heart failure among self-reporters of heart failure 
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Table 8. Prevalence of heart failure by method of ascertainment: The Atherosclerosis Risk in 
Communities (ARIC) Study, 2005-2012 (N = 9,347) 
 N Prevalence (%) 
95% Confidence 
Interval 
Self-reported heart failure 886 9.0 (8.4, 9.5) 
ARIC classified heart failure a 1,105 11.2 (10.6, 11.8) 
Administrative claims    
Hospitalized heart failure 
b 1,256 12.7 (12.0, 13.4) 
Hospitalized and 
outpatient heart failure c 1,839 
18.6 (17.8, 19.4) 
a Definite and probable acute decompensated heart failure and chronic stable heart failure ascertained 
from reviewed abstracted medical records 
b Centers for Medicare and Medicaid Services Medicare claims 
c International Classification of Disease, 9th Edition Clinical Modification (ICD-9-CM) code 428.x in 
any position present in the hospital record 
d ICD-9-CM 428.x in any position present in the hospital record or ICD-9-CM 428.x present in the 
outpatient record 
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Table 9. Heart failure classification for The Atherosclerosis Risk in Communities (ARIC) 
participants, 2005-2012 (N = 9,347) 
Self-reported  
heart failure 
ARIC classified  
heart failure a 
Heart failure 
hospitalizations 
identified from 
administrative claims b 
N (%) 
Yes Yes Yes 244 (2.6) 
Yes Yes No 82 (0.9) 
Yes No Yes 48 (0.5) 
Yes No No 275 (2.9) 
No Yes Yes 318 (3.4) 
No Yes No 180 (1.9) 
No No Yes 236 (2.5) 
No No No 7,964 (85.2) 
a Definite and probable acute decompensated heart failure and chronic stable heart failure ascertained 
from reviewed abstracted medical records 
b International Classification of Disease, 9th Edition Clinical Modification (ICD-9-CM) code 428.x in 
any position present in the hospital record 
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CHAPTER 6: MANUSCRIPT #2, TEMPORAL TRENDS IN HEART FAILURE: THE USE OF 
EMERGENCY DEPARTMENTS AND OUTPATIENT CLINICS 
6.1 Introduction  
Heart failure is the leading hospital discharge diagnosis among Medicare beneficiaries, which is 
reported to represent an increase of 155% over the past 20 years [9]. In response to high numbers of heart 
failure hospitalizations, the Centers for Medicare and Medicaid Services (CMS) initiated public reporting 
of hospital readmission rates in 2009. In 2010, reimbursement provided to hospitals by CMS were 
reduced proportionately to the hospitals’ heart failure readmission rates [10].  
Strategies to reduce heart failure-related hospital admissions and readmissions include enhanced 
efforts to improve management of heart failure in the outpatient setting, through effective management in 
ambulatory care clinics and emergency departments [26, 27]. It has been argued that enhanced diagnostic 
and therapeutic tools in the ambulatory care setting allow for patients with heart failure to be effectively 
managed without admission to a hospital, and thus reduce heart failure related hospitalizations and related 
costs [29-35]. It has also been posited that policy changes in financial reimbursements for heart failure 
hospital readmissions may have prompted an increase in heart failure management in the emergency 
department without hospitalizations [26].  
The objective of this study was to quantify incidence rates and period prevalence as well as 
temporal trends, of heart failure seen in ambulatory care clinics and emergency departments in a national 
probability sample of Medicare beneficiaries from 2007 to 2014.   
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6.2 Methods 
6.2.1 Study Population 
The analytic cohort was derived from a random 20% of all Medicare beneficiaries ages 65 years 
and older with Medicare fee-for-service Parts A, B, and D coverage for at least one calendar month 
during 2007-2014. Once a beneficiary met this selection criterion, all available fee-for-service claims and 
death data were included from that point through the end of 2014, disenrollment from Medicare fee-for-
service Parts A and B, or death, whichever came first.  
We obtained information concerning beneficiary enrollment in fee-for-service Medicare from 
monthly indicators of enrollment in Part A and Part B from the annual Medicare Beneficiary Summary 
files. Continuous enrollment periods were created to indicate uninterrupted fee-for-service coverage as 
well as lack of enrollment in a Medicare Advantage (HMO) plan. Medicare Provider Annual Review 
(MedPAR, Part A), Carrier, and Outpatient files (Part B) were merged with denominator files containing 
demographic and enrollment information including race, date of birth, sex, and enrollment start and end 
dates.  
6.2.2 Eligibility 
To estimate yearly heart failure incidence rates, beneficiaries were included if they were enrolled 
in continuous Medicare fee-for-service Parts A and B for ≥ 2 years. If a beneficiary had ≥1 enrollment 
period, the first enrollment period ≥ 2 years was included. To estimate yearly heart failure period-
prevalence, beneficiaries were included in the study sample (denominator) if they had any medical claim 
and were enrolled in Medicare fee-for-service Parts A and B for at least one calendar month during the 
applicable year. If a beneficiary had gaps in enrollment, all unique fee-for-service enrollment periods 
were included.  
6.2.3 Heart Failure Events 
Outpatient heart failure was identified from claims with Current Procedural Terminology (CPT) 
Evaluation and Management service codes for new and established outpatient visits (99201-99205), 
consultations (99241-99245), and established preventive medicine visits (99395-99397) matched with 
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Carrier (Part B) claims as well as claims for outpatient services provided through the Federally Qualified 
Healthcare Center (520-521). Using provider specialty codes to identify provider types, outpatient visits 
included visits to primary care physicians and cardiologists, visits to the emergency department that did 
not end in a hospital admission (routine discharge), and observation stays. Visits to primary care 
physicians and cardiologists were classified as clinic visits. Emergency department visits that did not 
result in a hospitalization or observation stays were classified as emergency department visits.  
Heart failure-related claims were identified using heart failure-specific International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes 428.x in any 
position in the record. An incident heart failure visit was defined as the first heart failure claim observed 
after the first two years of fee-for-service enrollment free of a heart failure claim. If a beneficiary was 
hospitalized for heart failure (ICD-9-CM code 428.x in any position) or was seen in the emergency 
department or clinic for heart failure during the first two years of fee-for-service enrollment, they were 
classified as having prevalent heart failure. Beneficiaries with prevalent heart failure were not eligible for 
an incident heart failure-related visit and thus excluded. Establishment of this look-back period was 
designed to reduce misclassification of prevalent heart failure as incident [122].   
6.2.4 Statistical Analysis 
Descriptive characteristics were expressed as counts of observations and percentages. Incidence 
rates per 1,000 person-years and 95% CIs were estimated by dividing the number of incident visits by 
person-time contributed by Medicare beneficiaries enrolled in a given year. Yearly trends in heart failure 
period prevalence and corresponding 95% confidence intervals (CI) were estimated by dividing the 
number of individuals with a heart failure-related visit in a given year by the total number of beneficiaries 
enrolled in Medicare fee-for-service in our sample. Cochran-Armitage tests for trend were used to 
estimate trends of heart failure period prevalence and incidence over time. The analyses and presentation 
of results were stratified by sex, age group (65-74, 75-79, 80-84, and ≥85 years), and race (white, black, 
Hispanic, Asian, and Native American). Prevalence ratios (PR) and incidence rate ratios (IRR) were 
estimated to determine differences of period prevalence and incidence between sex, age, and race groups.  
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All analyses were conducted using SAS V9.3 (SAS Inc. Cary, North Carolina). 
6.3 Results 
The yearly number of CMS Medicare fee-for-service beneficiaries in the 20% random sample 
increased from 2,599,507 in 2007 to 3,641,545 in 2014 (Table 10). Women accounted for over 60% of 
beneficiaries across all years and the distribution of age was similar from 2007-2014. The distribution of 
white (84.3%), black (8.5%), Hispanic (2.5%), Asian (2.6%), and Native American (0.4%) beneficiaries 
was also similar across years.  
6.3.1 Incidence 
6.3.1.1 Heart Failure-Related Ambulatory Care Visits 
Among Medicare fee-for-service beneficiaries, incidence of heart failure in ambulatory clinics 
decreased inconsistently over the study period. From 2008 (31.3 per 1,000 person years, 95% CI: 31.0, 
31.5) to 2012 (23.3 per 1,000 person years, 95% CI: 23.1, 23.5), incidence decreased with a subsequent 
increased in 2013 (27.0 per 1,000 person years, 95% CI: 26.8, 27.1), with a final decrease in 2014 (24.5 
per 1,000 person years, 95% CI: 24.3, 24.7, Figure 7). During that period, incidence trends among all 
gender, age, and race groups were similar to the overall trend (Figure 7). Incidence of heart failure from 
ambulatory clinics was incrementally higher among older age groups and was higher among black, Native 
American, and Asian, as compared to white, beneficiaries (Table 11).  
6.3.1.2 Heart Failure-Related Emergency Department Visits 
From 2008 to 2014, the incidence of heart failure-related emergency department visits, not 
resulting in a hospitalization, increased from 9.9 per 1,000 person-years (95% CI: 9.8, 10.0) to 13.0 per 
1,000 person-years (95% CI: 12.9, 13.2) among Medicare fee-for-service beneficiaries (p for trend < 
0.0001, Figure 8). During that time, incidence of heart failure in emergency departments was similar by 
gender (Table 12), increasing over the study period for both men (p for trend < 0.0001) and women (p for 
trend < 0.0001, Figure 8). The incidence of heart failure-related emergency department visits, not 
resulting in a hospitalization, increased over time and was incrementally higher among older age groups 
(Figure 8). The incidence of heart failure-related emergency department visits, not resulting in a 
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hospitalization, was higher among black and Native American, as compared to white beneficiaries for all 
years of the study period (Table 12). Conversely, the incidence of heart failure-related emergency 
department visits was lower among Asian and Hispanic, as compared to white, beneficiaries. The 
incidence of heart failure in emergency departments increased over the study period among all race 
groups (Figure 8).  
6.3.2 Period Prevalence 
6.3.2.1 Heart Failure-Related Ambulatory Care Visits 
Overall, the period prevalence of beneficiaries with a heart failure claim in the ambulatory clinic 
decreased from 2007 (7.6%, 95% CI: 7.6, 7.7) to 2014 (6.3%, 95% CI: 6.3, 6.4, p for trend < 0.0001, 
Figure 9). During that time, period prevalence of heart failure observed in the ambulatory clinic was 
consistently higher among men compared to women across all years of the study period (Table 13). We 
observed an overall decrease in period prevalence for both genders (Figure 9). Similarly, the period 
prevalence of heart failure observed in the ambulatory clinic decreased from 2007-2014 for all age groups 
(p for trend < 0.0001, Figure 9). A graded increase in period prevalence was observed from the youngest 
to the oldest age groups (Table 13). Period prevalence of beneficiaries with a heart failure claim in the 
ambulatory clinic was higher among black, Native American, and Asian beneficiaries compared to white 
beneficiaries throughout the study period (Table 13) and decreased from 2007 to 2014 among all race 
groups (Figure 9).  
6.3.2.2 Heart Failure-Related Emergency Department Visits 
Overall, the period prevalence of CMS Medicare beneficiaries 65 years and older who were 
admitted to the emergency department for heart failure without a subsequent hospitalization increased 
from 2007 (2.0%) to 2014 (2.1%, Figure 10). Though there was only an increase of 0.1%, the increase in 
period prevalence for heart failure-related emergency department visits was statistically significant due to 
large sample size. We considered period prevalence stable during the study period. During that time, 
period prevalence of heart failure-related emergency department visits was similar among men and 
women (Table 14) and was stable over time (Figure 10). Trends in emergency department heart failure 
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period prevalence remained stable over the study period for all age groups, and incrementally increased 
with beneficiary age (Figure 10).  Black and Native American beneficiaries had a higher and Asian and 
Hispanic beneficiaries had a lower prevalence of heart failure-related emergency department visits 
compared to their white counterparts (Table 14). The period prevalence of heart failure was stable over 
the study period for white beneficiaries during which we observed an increase in period prevalence 
among all other race groups (Figure 10).  
6.4 Discussion 
To complement previously reported temporal trends of hospitalized heart failure, we provide 
comprehensive incidence and period prevalence estimates of heart failure in ambulatory clinics and 
emergency departments from 2007 to 2014 in a probability sample of fee-for-service Medicare part A, B, 
and D beneficiaries in the United States. Substantial numbers of Medicare beneficiaries were seen in the 
ambulatory clinic and emergency department settings for heart failure during the study period. The 
temporal trend in the incidence of heart failure-related ambulatory clinic visits varied somewhat over 
time. An initial decrease in incident heart failure in ambulatory clinics was observed during the first four 
years of the study period (2008 to 2011) with a subsequent increase until the end of the study period 
among all race, sex, and age groups. Overall, the incidence of heart failure identified from emergency 
department visits modestly increased throughout the study period among all race, sex, and age groups. 
Although the period prevalence of heart failure seen in emergency departments was observe to be stable 
from 2007 to 2014, a slight increase was noted among black beneficiaries. During the same time, yearly 
period prevalence of heart failure in ambulatory clinics decreased overall and among all race, sex, and age 
groups.  
Heart failure related hospitalizations (ICD-9-CM code 428.x in the primary and any position) in 
the United States increased from 2001 to 2009, partly explained by the large number of re-hospitalizations 
among patients with heart failure [123]. In response to increasing heart failure hospitalizations, CMS 
began public reporting of all-cause readmission rates after heart failure hospitalizations in 2009, followed 
by an establishment of financial penalties for hospitals with the highest readmission rates during the first 
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30 days after discharge in 2010 [10]. Extant reports suggest that following initiatives to decrease heart 
failure rehospitalizations, rates of hospital admissions for heart failure (ICD-9-CM code 428.x in the 
primary position) have declined, and trends of heart failure related hospitalizations (ICD-9-CM code 
428.x in non-primary positions) have been stable [36, 80, 123, 124]. In parallel, incidence of hospitalized 
heart failure has decreased [9, 73, 74, 89, 124-126].  
It can be postulated that the observed decreases in hospitalized heart failure may be accompanied 
by an increase of incident heart failure seen in ambulatory care clinics, and/or in emergency departments 
without a subsequent hospital admission. The observed increase of incidence of heart-failure related 
emergency department visits from 2007 to 2014 is consistent with the interpretation that emergency 
department admissions may compensate for the reported decline in heart failure hospitalizations in the 
United States. Although such an approach to reduce heart failure-related hospitalizations is neither 
desirable nor cost-efficient, an increase in incidence of heart failure in emergency departments, without a 
subsequent admission to the hospital, may represent a deliberate or unintended strategy to decrease 
hospitalizations for heart failure and related costs.   
While the diagnosis and management of heart failure in ambulatory clinics is the better 
alternative, the lack of clear temporal trends in the incidence of heart failure in ambulatory clinics, paired 
with a decline in the annual period prevalence of heart failure-related ambulatory clinic visits, suggest that 
ambulatory clinics are not absorbing the care of heart failure patients that are not hospitalized. While such 
an interpretation is plausible, it is important to note that our characterization of heart failure from 
administrative claims is incomplete. Because information on clinical characteristics, functional measures, 
comorbidities, biomarkers, and patient history are not available in administrative claims, we were not able 
to evaluate disease severity nor the need for urgent or emergent care versus care in an ambulatory setting. 
While lacking information on heart failure severity, the temporal trends observed from 2007 to 2014 
suggest a modest decrease in the use of ambulatory clinics for heart failure care and a decrease in period 
prevalence. In the context of a parallel increase in the incidence of heart failure seen emergency 
departments it seems reasonable to conclude that opportunities for detection and management of heart 
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failure in in ambulatory clinics are not being realized, limiting the opportunities for management of 
patients with heart failure to prevent decompensation and emergency department admission [10, 127].  
There are alternative interpretations for the observed decrease in the prevalence of heart failure 
seen in ambulatory care clinics among Medicare beneficiaries. More readily available diagnostic tests in 
the ambulatory care setting may improve differential diagnosis and reduce a misclassification of patients 
who present with symptoms suggestive of heart failure. Greater diagnostic accuracy could result in 
reductions in the use of diagnostic codes related to heart failure, accompanied by opposing trends in 
diagnostic codes for conditions with similar signs and symptoms, such as chronic obstructive pulmonary 
disease. This motivates further research that considers cardiorespiratory syndromes.   
As a further consideration, favorable trends in blood pressure control and management paired 
with reductions in cardiovascular diseases that are precursors of heart failure may have contributed to a 
lower incidence of heart failure in the ambulatory care setting. Modest improvements in blood pressure 
control and awareness have been documented [4] and cardiovascular disease incidence has decreased [4], 
although other risk factors for heart failure such as diabetes, obesity, and physical activity have worsened 
over time [4]. Research is needed to better understand the role of the factors known to predict heart failure 
in the population burden of heart failure.  
Replication of our results in other populations and payer settings is warranted. Because our study 
sample only included Medicare beneficiaries enrolled in fee-for-service Parts A, B, and D, we were not 
able to address heart failure encounters among other individuals not enrolled in Medicare, enrolled in 
Medicare Advantage, or those enrolled only in Medicare fee-for-service Parts A and B. It has been 
reported however that few differences exist between Medicare beneficiaries enrolled in fee-for-service 
parts A, B, and D compared to those not enrolled in part D and those enrolled in Medicare Advantage. 
Part D enrollees have lower incomes than non-part D enrollees (ResDAC.com) and Medicare Advantage 
beneficiaries are less likely to reside in urban areas, are 30% less likely to use the emergency room, and 
spend 20% less days in an inpatient facility [128].  
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6.5 Conclusion  
The incidence of heart failure seen in ambulatory clinics has been mostly stable from 2008 to 
2014. In contrast, the incidence of heart failure seen in emergency departments without a subsequent 
hospitalization increased among Medicare beneficiaries during this time period. The period prevalence of 
beneficiaries with heart failure-related ambulatory care clinic visits decreased from 2007 to 2014. During 
the same period, the period prevalence of beneficiaries with heart failure-related emergency department 
visits was stable. These diverging temporal trends in patterns of care for heart failure may reflect the 
effect of policies designed to reduce hospitalizations for heart failure.  Future research should include 
formal evaluation of the strategies currently in place to reduce heart failure re-hospitalizations and 
promote the diagnosis and management of heart failure in the ambulatory setting. 
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Table 10. Descriptive characteristics of a 20% sample of Medicare fee-for-service beneficiaries with parts A-D (2007-2013) 
 Year 
 2007 2008 2009 2010 2011 2012 2013 2014 
 N = 2,599,507 N = 2,625,721 N = 2,646,537 N = 2,725,365 N = 2,851,833 N = 3,006,190 N = 3,480,786 N = 3,641,545 
 N % N % N % N % N % N % N % N % 
% Female  1,692,752 (65.1) 1,695,112 (64.6) 1,693,576 (64.0) 1,728,964 (63.4) 1,791,426 (62.8) 1,869,845 (62.2) 2,126,929 (61.1) 2,208,626 (60.7) 
Age (years) a                 
65-69  653,566 (25.1) 667,806 (25.4) 681,498 (25.8) 706,914 (25.9) 756,296 (27.8) 801,252 (26.7) 958,236 (27.5) 1,024,751 (28.1) 
70-74  571,036 (22.0) 584,589 (22.3) 598,813 (22.6) 627,845 (23.0) 663,974 (24.4) 716,430 (23.8) 835,122 (24.0) 882,796 (24.2) 
75-79  506,864 (19.5) 495,497 (18.9) 487,908 (18.4) 496,097 (18.2) 512,502 (18.8) 541,568 (18.0) 629,500 (18.1) 658,519 (18.1) 
80-84  415,529 (16.0) 417,722 (15.9) 415,601 (15.7) 419,321 (15.4) 427,399 (15.7) 436,368 (14.5) 485,125 (13.9) 490,261 (13.5) 
≥85  452,512 (17.4) 460,107 (17.5) 462,717 (17.5) 475,188 (17.4) 491,662 (18.0) 510,572 (17.0) 572,803 (16.5) 585,218 (16.1) 
Race                 
White 2,183,429 (84.0) 2,211,950 (84.2) 2,230,428 (84.3) 2,292,229 (84.1) 2,402,737 (84.3) 2,534,870 (84.3) 2,944,314 (84.6) 3,077,825 (84.5) 
Black 232,310 (8.9) 224,117 (8.5) 219,949 (8.3) 228,063 (8.4) 233,755 (8.2) 243,227 (8.1) 284,063 (8.2) 291,279 (8.0) 
Hispanic 64,428 (2.5) 70,006 (2.6) 72,785 (2.6) 72,785 (2.7) 75,285 (2.6) 78,005 (2.6) 82,162 (2.4) 84,617 (2.3) 
Asian 70,027 (2.7) 70,294 (2.7) 72,336 (2.7) 72,336 (2.7) 73,757 (2.6) 74,315 (2.5) 75,767 (2.2) 76,766 (2.1) 
Native 
American 11,185 (0.4) 11,889 (0.4) 12,239 (0.4) 12,239 (0.4) 12,535 (0.4) 12,818 (0.4) 13,701 (0.4) 14,144 (0.4) 
Other 34,915 (1.3) 40,409 (1.4) 42,716 (1.5) 42,716 (1.6) 45,389 (1.6) 49,233 (1.6) 57,026 (1.6) 61,796 (1.7) 
Missing 3,213 (0.1) 3,562 (0.1) 4,997 (0.1) 4,997 (0.2) 8,375 (0.3) 13,722 (0.5) 23,753 (0.7) 35,118 (1.0) 
a Age was recorded on July 1 of a given year 
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Table 11. Incidence rate ratios: heart failure observed in ambulatory clinics, 20% sample of Medicare fee-for-service beneficiaries with 
parts a-d (2008-2013) 
 Year 
 2008 2009 2010 2011 2012 2013 2014 
 N = 2,288,800 N = 2,319,099 N = 2,383,195 N = 2,496,627 N = 2,644,339 N = 2,952,991 N = 2,811,607 
 IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI 
Sex                      
Female 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   
Male  1.2 (1.2 1.2) 1.2 (1.2 1.2) 1.2 (1.2 1.2) 1.2 (1.2 1.2) 1.2 (1.2 1.2) 1.3 (1.3 1.3) 1.3 (1.3 1.3) 
Age (years)                      
65-69 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   
70-74 1.6 (1.6 1.6) 1.5 (1.5 1.6) 1.5 (1.4 1.5) 1.4 (1.3 1.4) 1.4 (1.3 1.4) 1.5 (1.4 1.5) 1.1 (1.1 1.1) 
75-79 2.2 (2.1 2.3) 2.1 (2.0 2.1) 2.0 (1.9 2.0) 1.9 (1.9 2.0) 2.0 (1.9 2.0) 2.1 (2.1 2.2) 1.6 (1.5 1.6) 
80-84 2.9 (2.9 3.0) 2.7 (2.6 2.8) 2.6 (2.5 2.7) 2.6 (2.5 2.6) 2.7 (2.6 2.8) 3.0 (2.9 3.1) 2.2 (2.1 2.3) 
≥85 3.7 (3.6 3.8) 3.4 (3.3 3.5) 3.3 (3.2 3.4) 3.3 (3.2 3.4) 3.5 (3.4 3.6) 4.0 (3.9 4.1) 2.9 (2.9 3.0) 
Race                      
White 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   
Black 1.1 (1.1 1.1) 1.1 (1.1 1.2) 1.1 (1.1 1.2) 1.2 (1.2 1.2) 1.2 (1.2 1.3) 1.2 (1.2 1.2) 1.2 (1.2 1.3) 
Hispanic 0.8 (0.7 0.8) 0.8 (0.7 0.8) 0.8 (0.8 0.9) 0.8 (0.8 0.9) 0.8 (0.7 0.8) 0.7 (0.7 0.7) 0.8 (0.7 0.8) 
Asian 1.1 (1.1 1.2) 1.2 (1.1 1.2) 1.1 (1.1 1.2) 1.1 (1.1 1.2) 1.1 (1.0 1.2) 0.9 (0.8 0.9) 1.0 (0.9 1.0) 
Native 
American 1.1 (1.0 1.2) 1.1 (1.0 1.2) 1.2 (1.1 1.3) 1.2 (1.1 1.3) 1.1 (1.0 1.3) 1.1 (1.0 1.2) 1.1 (1.0 1.2) 
Abbreviations: Confidence interval (CI); Incidence rate ratios (IRR) 
Ambulatory clinic visits included visits to primary care physicians and cardiologists 
Age was recorded on July 1 of a given year 
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Table 12. Incident rate ratios: heart failure observed in emergency departments, 20% sample of Medicare fee-for-service beneficiaries 
with parts a-d (2008-2013) 
 Year 
 2008 2009 2010 2011 2012 2013 2014 
 N = 2,288,818 N = 2,340,599 N = 2,426,043 N = 2,560,615 N = 2,729,579 N = 3,060,200 N = 2,950,865 
 IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI 
Sex                      
Female 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   
Male  0.9 (0.8 0.9) 0.9 (0.9 1.0) 0.9 (0.9 0.9) 1.0 (0.9 1.0) 1.0 (1.0 1.0) 1.0 (1.0 1.1) 1.1 (1.4 1.1) 
Age (years)                      
65-69 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   
70-74 1.5 (1.4 1.5) 1.4 (1.3 1.4) 1.3 (1.3 1.4) 1.2 (1.2 1.3) 1.3 (1.2 1.3) 1.3 (1.3 1.4) 1.1 (1.0 1.1) 
75-79 2.1 (2.0 2.2) 2.0 (1.9 2.1) 1.9 (1.8 2.0) 1.8 (1.7 1.9) 1.9 (1.8 2.0) 2.0 (1.9 2.0) 1.6 (1.5 1.6) 
80-84 3.1 (2.9 3.2) 3.0 (2.8 3.1) 2.8 (2.7 2.9) 2.6 (2.5 2.8) 2.8 (2.7 3.0) 3.0 (2.8 3.1) 2.4 (2.3 2.4) 
≥85 3.6 (3.5 3.8) 3.6 (3.4 3.7) 3.5 (3.4 3.6) 3.5 (3.4 3.7) 3.6 (3.5 3.8) 3.6 (3.5 3.8) 3.6 (3.4 3.7) 
Race                      
White 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   
Black 1.5 (1.4 1.5) 1.5 (1.4 1.5) 1.5 (1.5 1.6) 1.5 (1.4 1.5) 1.5 (1.5 1.6) 1.5 (1.5 1.6) 1.5 (1.4 1.5) 
Hispanic 0.3 (0.2 0.3) 0.4 (0.3 0.4) 0.4 (0.3 0.4) 0.4 (0.4 0.5) 0.4 (0.3 0.4) 0.4 (0.4 0.5) 0.5 (0.4 0.5) 
Asian 0.8 (0.7 0.9) 0.8 (0.7 0.9) 0.8 (0.7 0.9) 0.8 (0.7 0.9) 0.9 (0.8 1.0) 0.9 (0.8 0.9) 0.9 (0.8 1.0) 
Native 
American 1.4 (1.2 1.6) 1.5 (1.2 1.7) 1.3 (1.1 1.5) 1.1 (1.0 1.4) 1.4 (1.2 1.6) 1.5 (1.3 1.7) 1.5 (1.3 1.7) 
Abbreviations: Confidence interval (CI); Incidence rate ratios (IRR) 
Emergency department visits included visits to the emergency department that did not end in a hospital admission (routine discharge) and observation stays 
Age was recorded on July 1 of a given year 
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Table 13. Prevalence ratios: heart failure observed in ambulatory clinics, 20% sample of Medicare fee-for-service beneficiaries with parts 
a-d (2007-2013) 
 Year 
 2007 2008 2009 2010 2011 2012 2013 2014 
 N = 2,599,507 N = 2,625,721 N = 2,646,537 N = 2,725,365 N = 2,851,833 N = 3,006,190 N = 3,480,786 N = 3,641,545  
 PR 95% CI PR 95% CI PR 95% CI PR 95% CI PR 95% CI PR 95% CI PR 95% CI PR 95% CI 
Sex                         
Female 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   1.0   
Male  1.3 (1.3 1.4) 1.4 (1.3 1.4) 1.4 (1.3 1.4) 1.4 (1.3 1.4) 1.4 (1.3 1.4) 1.4 (1.3 1.4) 1.4 (1.4 1.4) 1.4 (1.4 1.4) 
Age (years)                         
65-69 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   1.0   
70-74 1.4 (1.4 1.4) 1.4 (1.4 1.4) 1.4 (1.3 1.4) 1.4 (1.3 1.4) 1.3 (1.3 1.4) 1.4 (1.3 1.4) 1.4 (1.4 1.4) 1.4 (1.4 1.4) 
75-79 1.8 (1.8 1.9) 1.9 (1.8 1.9) 1.9 (1.8 1.9) 1.9 (1.8 1.9) 1.8 (1.8 1.9) 1.9 (1.9 1.9) 1.9 (1.9 2.0) 2.0 (2.0 2.0) 
80-84 2.3 (2.3 2.4) 2.4 (2.4 2.4) 2.4 (2.4 2.4) 2.4 (2.4 2.4) 2.4 (2.4 2.5) 2.5 (2.5 2.5) 2.6 (2.6 2.7) 2.7 (2.6 2.7) 
≥85 2.9 (2.8 2.9) 2.9 (2.9 3.0) 2.9 (2.9 3.0) 2.9 (2.9 3.0) 3.0 (3.0 3.0) 3.1 (3.1 3.2) 3.3 (3.3 3.4) 3.4 (3.4 3.5) 
Race                         
White 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   1.0   
Black 1.2 (1.1 1.1) 1.1 (1.1 1.1) 1.2 (1.2 1.2) 1.2 (1.2 1.3) 1.2 (1.3 1.3) 1.3 (1.3 1.3) 1.3 (1.3 1.3) 1.3 (1.3 1.3) 
Hispanic 0.8 (0.9 0.9) 0.9 (0.9 0.9) 0.8 (0.8 0.8) 0.8 (0.8 0.8) 0.8 (0.8 0.8) 0.8 (0.8 0.8) 0.8 (0.8 0.8) 0.8 (0.8 0.8) 
Asian 1.1 (1.1 1.1) 1.1 (1.1 1.1) 1.1 (1.1 1.1) 1.1 (1.1 1.1) 1.1 (1.1 1.1) 1.1 (1.1 1.1) 1.0 (1.0 1.0) 1.0 (1.0 1.0) 
Native 
American 1.2 (1.3 1.3) 1.3 (1.3 1.3) 1.2 (1.1 1.3) 1.2 (1.1 1.3) 1.2 (1.1 1.3) 1.2 (1.1 1.3) 1.2 (1.2 1.3) 1.2 (1.1 1.3) 
Abbreviations: Confidence interval (CI); Prevalence ratios (PR) 
Ambulatory clinic visits included visits to primary care physicians and cardiologists 
Age was recorded on July 1 of a given year 
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Table 14. Prevalence ratios: heart failure observed in emergency departments, 20% sample of Medicare fee-for-service beneficiaries with 
parts a-d (2007-2013) 
 Year 
 2007 2008 2009 2010 2011 2012 2013 2014 
 N = 2,599,507 N = 2,625,721 N = 2,646,537 N = 2,725,365 N = 2,851,833 N = 3,006,190 N = 3,480,786 N = 3,641,545 
 PR 95% CI PR 95% CI PR 95% CI PR 95% CI PR 95% CI PR 95% CI PR 95% CI PR 95% CI 
Sex                         
Female 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   1.0   
Male  1.0 (1.0 1.1) 1.0 (1.0 1.0) 1.0 (1.0 1.1) 1.0 (1.0 1.0) 1.0 (1.0 1.0) 1.0 (1.0 1.1) 1.1 (1.0 1.1) 1.1 (1.1 1.1) 
Age (years)                         
65-69 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   1.0   
70-74 1.3 (1.3 1.4) 1.3 (1.3 1.4) 1.3 (1.3 1.3) 1.3 (1.2 1.3) 1.3 (1.2 1.3) 1.3 (1.3 1.3) 1.3 (1.3 1.4) 1.3 (1.3 1.4) 
75-79 1.7 (1.7 1.8) 1.8 (1.7 1.8) 1.8 (1.7 1.8) 1.7 (1.7 1.8) 1.7 (1.7 1.8) 1.8 (1.7 1.8) 1.8 (1.8 1.9) 1.8 (1.8 1.9) 
80-84 2.4 (2.4 2.5) 2.4 (2.4 2.5) 2.5 (2.4 2.5) 2.4 (2.3 2.5) 2.3 (2.3 2.4) 2.5 (2.4 2.5) 2.6 (2.5 2.6) 2.6 (2.6 2.7) 
≥85 3.7 (3.6 3.8) 3.8 (3.7 3.9) 3.7 (3.6 3.8) 3.6 (3.5 3.7) 3.6 (3.5 3.7) 3.7 (3.6 3.8) 3.9 (3.8 4.0) 3.9 (3.8 4.0) 
Race                         
White 
(ref) 1.0   1.0   1.0   1.0   1.0   1.0   1.0   1.0   
Black 1.5 (1.5 1.5) 1.6 (1.5 1.6) 1.6 (1.6 1.7) 1.7 (1.7 1.8) 1.8 (1.7 1.8) 1.8 (1.8 1.8) 1.8 (1.8 1.8) 1.8 (1.8 1.9) 
Hispanic 0.3 (0.3 0.4) 0.3 (0.3 0.3) 0.3 (0.3 0.4) 0.4 (0.3 0.4) 0.4 (0.4 0.4) 0.4 (0.3 0.4) 0.4 (0.4 0.5) 0.5 (0.4 0.5) 
Asian 0.7 (0.7 0.8) 0.8 (0.8 0.8) 0.7 (0.7 0.8) 0.8 (0.7 0.8) 0.8 (0.8 0.8) 0.8 (0.8 0.9) 0.8 (0.8 0.9) 0.9 (0.8 0.9) 
Native 
American 1.4 (1.2 1.6) 1.5 (1.4 1.7) 1.7 (1.5 1.8) 1.5 (1.4 1.7) 1.4 (1.3 1.6) 1.6 (1.4 1.8) 1.7 (1.5 1.9) 1.7 (1.6 1.9) 
Abbreviations: Confidence interval (CI); Prevalence ratios (PR) 
Emergency department visits included visits to the emergency department that did not end in a hospital admission (routine discharge) and observation stays 
Age was recorded on July 1 of a given year 
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Figure 7. Crude incidence rates for heart failure related ambulatory clinic visits (ICD-9-CM code 42.8.x), CMS Medicare fee-for-service 
beneficiaries (2008-2014) 
 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
Ambulatory clinic visits included visits to primary care physicians and cardiologists 
Heart failure-related claims were identified using heart failure-specific ICD-9-CM codes 428.x in any position in the record 
Incidence heart failure was defined as the first heart failure claim observed after the first two years of fee-for-service enrollment free of a heart failure claim 
Age was recorded on July 1 of a given year 
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Figure 8. Crude incidence rates for heart failure related emergency department visits (ICD-9-CM code 428.x), CMS Medicare fee-for-
service beneficiaries (2008-2014) 
 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
Emergency department visits included visits to the emergency department that did not end in a hospital admission (routine discharge) and observation stays 
Heart failure-related claims were identified using heart failure-specific ICD-9-CM codes 428.x in any position in the record 
Incidence heart failure was defined as the first heart failure claim observed after the first two years of fee-for-service enrollment free of a heart failure claim 
Age was recorded on July 1 of a given year 
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Figure 9. Crude period prevalence for heart failure related ambulatory clinic visits (ICD-9-CM code 42.8.x), CMS Medicare fee-for-
service beneficiaries (2007-2014) 
 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
Ambulatory clinic visits included visits to primary care physicians and cardiologists 
Heart failure-related claims were identified using heart failure-specific ICD-9-CM codes 428.x in any position in the record 
Age was recorded on July 1 of a given year 
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Figure 10. Crude period prevalence for heart failure related emergency department visits (ICD-9-CM code 428.x), CMS Medicare fee-for-
service beneficiaries (2007-2014) 
 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
Emergency department visits included visits to the emergency department that did not end in a hospital admission (routine discharge) and observation stays 
Heart failure-related claims were identified using heart failure-specific ICD-9-CM codes 428.x in any position in the record 
Age was recorded on July 1 of a given year 
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CHAPTER 7: CONCLUSIONS AND PUBLIC HEALTH IMPLICATIONS 
Heart failure is a clinical syndrome characterized by signs and symptoms that greatly limit an 
individual’s quality of life, are often disabling, and are associated with reduced survival.  Due to the high 
prevalence of the disease and the frequent hospitalizations associated with it, heart failure is the leading 
hospital discharge diagnosis among Medicare patients. Reimbursement policies have been established to 
reduce heart failure-related hospitalizations and re-hospitalizations. The efforts to reduce re-
hospitalizations for heart failure highlight the need to understand the magnitude and temporal trends of 
care for heart failure in outpatient facilities as a means to complement the information on burden and 
temporal trends of hospitalizations associated with heart failure.   
7.1 Agreement of Self-Reported Heart Failure  
While monitoring the population burden and temporal trends in heart failure is necessary, 
identifying heart failure in population settings is difficult, costly, and prone to error. Self-report of 
physician-diagnosed heart failure has been used to quantify the burden of heart failure in the community. 
Given the complexity of heart failure diagnosis and classification however, it can be difficult for health 
professionals to accurately inform patients, and for patients to accurately report their heart failure status. 
One of the aims of this doctoral research was to estimate the agreement of self-reported heart failure with 
confirmation of heart failure by the interviewee’s health care provider, hospital medical record extraction, 
and the presence of heart failure ICD-9-CM codes in administrative claims, and to compare prevalence 
estimates of heart failure based on these methods of ascertainment.   
We examined the agreement of self-reported heart failure with physician confirmed heart failure, prior 
indications of heart failure in the patient’s health record, and heart failure identified from administrative 
claims. The agreement, measured by kappa, and the verification, measured by positive predicted value, 
were poor. Moreover, self-reported heart failure is insensitive, indicating that patients with heart failure 
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are unable to accurately recount their heart failure diagnosis. In contrast, self-reported heart failure is 
specific, indicating that patients without heart failure accurately recount their lack of a heart failure 
diagnosis. In contrast, prevalence estimates of self-reported heart failure are comparable to those 
estimated from hospitalizations with heart failure discharge diagnoses although actual “cases” of heart 
failure would be misclassified, since those reporting heart failure are not consistently those who 
experienced a heart failure hospitalization. For accurate population estimates of heart failure, self-reported 
heart failure data should be coupled with other information such as diagnostic tests or medical records or 
not used in population estimates.   
 Clinically, an effort among health care providers to more accurately convey to patients that they 
have heart failure are warranted. Advocacy campaigns such as “Know Your Number” 
(https://www.knowyournumber.com/) for other chronic, preventable diseases resulting in poor quality of 
life, declining productivity, and higher healthcare costs, have been established to help educate patients on 
their disease status. It is important for patients to know their heart failure status as well as the type of 
chronic heart disease. Similar education efforts can assist patients with their understanding of medications 
and treatment to help manage the syndrome as well as allow them to more effectively participate as users 
of this information.  
7.2 Temporal Trends of Outpatient Heart Failure  
 Large numbers of Medicare beneficiaries are seen in the outpatient setting for heart failure. We 
observed that the incidence of heart failure in the ambulatory clinic and emergency department was 
higher among older, black, and Native American beneficiaries. For all age, sex, and race groups, 
incidence was inconsistent from 2008 to 2014, but overall decreased. During the same period, emergency 
department incidence increased among all groups analyzed. Period prevalence was higher among older, 
black, and Native American beneficiaries. The period prevalence of beneficiaries with a heart failure-
related ambulatory clinic visit decreased from 2007 to 2014. During the same period the period 
prevalence was stable in the emergency department whereas the heart failure period prevalence in 
emergency departments increased slightly among minority beneficiaries.  
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The incidence of heart failure in emergency departments without a hospital admission increased 
during the observation period. This increase, paired with other research showing a decrease in 
hospitalized heart failure [9, 73, 74, 89, 124-126] may indicate the increase in incidence of heart failure 
seen in emergency departments may reflect a deliberate or unintended strategy to decrease 
hospitalizations for heart failure. If this interpretation holds it would be a sub-optimal and costly approach 
to reduce heart failure-related hospitalizations. A preferred approach for the detection and management of 
heart failure would be care in the ambulatory clinic. However, our results indicate little change in the 
incidence of heart failure in ambulatory clinics from 2008 to 2014, paired with a decline in annual period 
prevalence of heart failure-related ambulatory clinic visits.  Current  strategies for preventing heart failure 
hospitalizations do not seem to draw on the opportunities for heart failure detection and management in 
ambulatory clinics. 
7.3 Strengths  
 Several features contributed to make this research informative. The salient strength of this study is 
the assessment of the frequency of occurrence of heart failure as outpatient clinical encounters and its 
temporal trends.  Information on rates of heart failure in the outpatient setting is scarce, as the majority of 
research on quantifying the burden of heart failure examined inpatient care. Several recent studies reported 
that a significant proportion of the initial diagnoses and subsequent management of heart failure occurs in 
outpatient settings, however. Thus, this research focused on outpatient encounters to enable an examination 
of the total burden of heart failure as it relates to inpatient and outpatient care, contributing to an area of 
research that is mostly missing in the literature.  
Another strength of this study is the use of the ARIC study cohort, which is exceptionally well 
characterized regarding heart failure. The ARIC study has followed its participants since 1986 and has 
conducted cohort and community surveillance of heart failure since 2005, as well as annual telephone 
interviews for regular follow up on self-reported heart failure. Furthermore, the ARIC study linked its 
cohort participant data with the CMS Medicare claims database, by which ARIC participants enrolled in 
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CMS Medicare fee-for-service are linked to their inpatient and outpatient claims billed through Medicare, 
thus allowing for an additional form of heart failure surveillance.  
The use of a random 20% national sample of Medicare beneficiaries represents a further strength 
in assessing temporal information on Parts A, B, and D fee-for-service beneficiaries, i.e., a large proportion 
of all eligible individuals aged 65 and older in the US.  Population denominators are available for this 
population that enable estimation of rates of outpatient heart failure. Further, his sample facilitates 
extrapolation of our results to the total Medicare beneficiary population and to the US Medicare population.  
7.4 Limitations 
The ARIC study is conducted only in four geographically defined areas of the United States; thus, 
generalizability outside of Forsyth County, NC, Washington County, MD, Minneapolis, MN, and Jackson, 
MS likely is constrained. There are limitations to using the 20% random sample of CMS Medicare 
beneficiaries. We excluded individuals aged 65 years and older not enrolled in Medicare, enrolled in 
Medicare advantage, and only Medicare fee-for-service Parts A and B. The use of our Medicare sample 
will thus limit our generalizability to only Medicare beneficiaries enrolled in Parts A, B, and D. There is 
little information available comparing Part D beneficiaries with those not enrolled in Part D. It has been 
noted however that there is little difference between Medicare beneficiaries enrolled in fee-for-service 
compared to those enrolled in Medicare Advantage: Medicare Advantage beneficiaries are less likely to 
reside in urban areas and are about 30% less likely to use the emergency room and spend 20% fewer days 
in an inpatient facility [128]. Another limitation derived from our study sample is that it only includes 
claims following a beneficiary’s enrollment in Part D. For example, if a beneficiary enrolls in fee-for-
service Part A and B on January 1, 2008 but does not enroll in Part D until January 1, 2009, the claims 
billed in 2008 are missing.  
7.5 Future Work 
Future population estimates of heart failure should include outpatient heart failure encounters 
since exclusive reliance on inpatient estimates underestimates the burden of heart failure and present an 
incomplete profile of trends in heart failure occurrences over time.  To be more informative, population 
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estimates of heart failure should consider heart failure seen in ambulatory care, urgent care, cardiology 
visits, and emergency department visits that do not lead to hospitalization or observation stays to provide 
more information on the population burden of heart failure and its impact on the health care system.  
The information available in claims data was insufficient to establish heart failure severity or 
decompensation. Similarly, we did not determine the degree to which emergency department visits for 
heart failure represent decompensation and acute care, or substitution for care in an ambulatory clinic. 
The use of medical records may be a more appropriate avenue to answer these questions. Because of these 
limitations and constraints to the generalizability of our results, our findings should be replicated in other 
populations and payer settings, as well as among those without health insurance. A further line of inquiry 
to complement these questions would evaluate the case fatality of heart failure predominantly managed in 
the hospital, emergency department, and ambulatory clinic.  
Among Medicare beneficiaries enrolled in pasts A-D the incidence of heart failure-related visits 
to emergency rooms increased from 2008 to 2014, accompanied by a stable incidence of heart failure 
visits to ambulatory clinics, and a decline in the annual period prevalence of heart failure-related 
ambulatory clinic visits. This information, and an examination of the factors underlying these trends, 
should be considered in an evaluation of the strategies currently in place to reduce heart failure 
hospitalizations.  
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APPENDIX 1: DEFINITIONS OF HEART FAILURE CODES 
ICD-9-CM Diagnosis Codes for Heart Failure: Definitions 
Description Code 
 Heart failure 
 Congestive heart failure, unspecified   
 Left heart failure   
 Systolic heart failure 
 Systolic heart failure, unspecified   
 Acute systolic heart failure   
 Chronic systolic heart failure 
 Acute on chronic systolic heart failure   
 Diastolic heart failure 
 Diastolic heart failure, unspecified   
 Acute diastolic heart failure   
 Chronic diastolic heart failure   
 Acute on chronic diastolic heart failure   
 Combined systolic and diastolic heart failure 
 Combined systolic and diastolic heart failure, unspecified   
 Acute combined systolic and diastolic heart failure  
 Chronic combined systolic and diastolic heart failure   
 Acute on chronic combined systolic and diastolic heart failure   
 Heart failure, unspecified   
428 
428.0  
428.1  
428.2  
428.20  
428.22  
428.22  
428.23 
428.3  
 428.30   
 428.31   
 428.32   
 428.33   
 428.4  
 428.40   
 428.41   
 428.42   
 428.43  
 428.9  
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APPENDIX 2: ANNUAL FOLLOW-UP QUESTIONNAIRE FORM, VERSION L 
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APPENDIX 3: ANNUAL FOLLOW-UP QUESTIONNAIRE FORM, VERSION M 
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APPENDIX 4: PHYSICIAN HEART FAILURE SURVEY (PHF) 
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APPENDIX 5: INSTRUCTIONS FOR COMPLETING PHYSICIAN HEART FAILURE FORM (PHF) 
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APPENDIX 6: SELF-REPORTED HEART FAILURE LITERATURE REVIEW 
Author, year 
Country 
N= 
Age range (years) 
Study population 
Self-report assessment of 
heart failure 
 
Objective measure of 
heart failure 
Results Conclusion 
Okura, 2004 [38] 
United States 
2,037 
≥45 years 
Olmsted County, 
Minnesota (Rochester 
Epidemiology Project) 
Mailed questionnaire: "Has 
a medical provider ever 
told you that you had HF?" 
 
Inpatient and outpatient 
medical record review 
Sensitivity = 68.6% 
Specificity = 97.0% 
Positive Predicted Value = 
36.8% 
Agreement = 96.3% 
Self-reported HF prevalence = 
4.7% 
Medical record prevalence = 
2.5% 
Compared to other chronic 
diseases, CHF showed poor 
agreement with chart-
confirmed diagnosis of heart 
failure. 
 
Heart failure may be less 
familiar and less easily 
understood dx or nonspecific 
in symptoms. 
 
Survey questionnaire info on 
heart failure may be 
relatively unreliable and 
underscore the need for more 
effective methods for 
identifying persons with 
significant ventricular 
dysfunction. 
Merkin, 2007 [39] 
United States 
965 
Mean age = 58 years 
ESRD patients 
(CHOICE) 
In person questionnaire: 
"Have you ever been told 
by a doctor that you have 
heart failure?" 
 
Sensitivity = 54-60% 
Specificity = 91-97% 
Kappa = 0.43 
Self-reported HF prevalence = 
29% 
Reliance of patient self-
report without validation can 
lead to errors in 
determination of disease 
status and related inferences. 
This may affect enrollment 
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Author, year 
Country 
N= 
Age range (years) 
Study population 
Self-report assessment of 
heart failure 
 
Objective measure of 
heart failure 
Results Conclusion 
Medical record review and 
physician reports 
Medical record prevalence = 
46% 
eligibility in research studies 
and outcome analysis that 
depends on self-report for 
disease classification. Info 
may be used to determine the 
allocation of resources in 
studies to adjudicate specific 
dx or to evaluate studies that 
rely upon SR information.  
Baumeister, 2010 
[37] 
Germany 
7,124 
18-79 years 
German Health 
Survey, cross-
sectional 
In person questionnaire: 
"Which of the following 
diseases have you ever 
had?" (heart weakness, 
heart insufficiency)  
 
Thorough physical 
examination and lab data 
Sensitivity = 88.5% 
Specificity = 98.3% 
Positive Predicted Value = 
65.1% 
Negative Predicted Value = 
99.6% 
Kappa = 0.74 
Important to make a valid 
assessment of chronic 
diseases 
Muggah, 2007 [45] 
Canada 
85,549 
≥20 years 
Population based data 
from Ontario, Canada 
In person community health 
survey: "Identify if you 
have any one of a list of 
chronic health conditions." 
(heart failure) 
 
Health administrative data: 
1 hospital admission with 
428.x or 1 outpatient code 
followed within 2 years by 
Sensitivity = 26% 
Specificity = 99% 
Positive agreement = 34% 
Negative agreement = 99% 
Kappa = 0.33 
Self-reported HF prevalence = 
1.5% 
HF identified from 
administrative claims 
prevalence = 2.7% 
Discordance is large for 
disease with low prevalence  
Accuracy. Validity, and 
generalizability of chronic 
disease case ascertainment 
methods depends on the data 
source used; researchers 
should be mindful as to the 
implications of data sources 
on their results 
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Author, year 
Country 
N= 
Age range (years) 
Study population 
Self-report assessment of 
heart failure 
 
Objective measure of 
heart failure 
Results Conclusion 
another outpatient or 
hospital admission  
Teh, 2013 [40] 
New Zealand 
878 
Mean age = 82 years 
New Zealand cohort 
of octogenarians 
Standardized in person 
questionnaire: "Have you 
ever been told by a doctor 
that you have congestive 
heart failure?" 
 
Primary health care record - 
search of medical records 
from general practitioner 
and administrative hospital 
discharge diagnosis records 
(ICD-9-CM code 428.x) 
Kappa = 0.19 
Proportion of discordance = 
22% 
General practitioner notes 
may not record CHF 
accurately because of the 
complex nature of the 
condition. 
 
Patients do not have access to 
personal medical records and 
rely on recall; some may be 
given discharge summary 
with a lot of medical 
terminology. 
The Italian 
Longitudinal Study 
on Aging, 1997 [41] 
Italy 
The Italian 
Longitudinal Study on 
Aging 
In person questionnaire: 
"Has a doctor ever told you 
that you are affected by 
heart failure?" 
False positives: 
Men = 3.0%; Women = 2.6% 
Unreported cases: 
Men = 3.0%, Women = 4.1% 
Self-report survey 
questionnaires used to 
identify prevalent conditions 
are insensitive instruments. 
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Author, year 
Country 
N= 
Age range (years) 
Study population 
Self-report assessment of 
heart failure 
 
Objective measure of 
heart failure 
Results Conclusion 
5,632 
65-84 years 
 
Review of medical records  
Prevalence: 
Men = 5.4; Women = 7.3 
Simpson, 2003 [42] 
United States 
1,002 
≥65 years 
Women's health and 
aging study 
In person questionnaire: 
"Has a physician diagnosed 
you with heart failure?" 
 
Algorithm estimated from 
medications, hospital 
records, physician 
questionnaire, and 
echocardiogram 
Sensitivity = 47% 
Specificity = 95% 
Positive Predicted Value = 
63% 
Negative Predicted Value = 
93% 
Agreement = 90% 
Kappa = 0.48 
Self-reported HF prevalence = 
9% 
Algorithm prevalence = 12% 
In disabled older women, 
self-reported physician 
diagnosis of heart failure 
appears valid. Increasing 
comorbidity and age and 
decreasing cognition and 
education are associated with 
decreasing agreement 
Tisnado, 2006 [43] 
United States 
1,270 
18-70 years 
Pacific Business 
Group on Health 
Physician Value 
Check Survey 
Survey 
 
Review of all primary care 
provider and key specialty 
types of medical records 30 
months before survey 
Sensitivity = 31% 
Specificity = 94% 
Kappa = 0.3 
Agreement - 86% 
Self-reported HF prevalence = 
9% 
Medical record HF prevalence 
= 13% 
Either self-reported or medical 
record HF prevalence = 18% 
Patients may not have been 
familiar with the term and 
may not have known they 
had this diagnosis 
Heckbert, 2004 [44] 
United States 
50-79 years 
Women's Health 
Initiative 
Survey 
 
Sensitivity = 38% 
Positive Predicted Value = 
HF remains difficult to 
classify reliably, physician 
review of events with 
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Author, year 
Country 
N= 
Age range (years) 
Study population 
Self-report assessment of 
heart failure 
 
Objective measure of 
heart failure 
Results Conclusion 
Adjudicated medical 
records 
65% 
Kappa = 0.48 
hospital discharge codes for 
heart failure is an important 
source of validated events 
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APPENDIX 7: RATES OF OUTPATIENT HEART FAILURE LITERATURE REVIEW 
Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
Outpatient Heart Failure 
Senni, 1999 [129] 
United States 
248 
>65 years 
Rochester 
Epidemiology 
Project  1981 vs. 
1991 
 
Olmsted County, 
Minnesota where 
the Rochester 
Epidemiology 
Project provides 
passive surveillance 
of the population for 
health outcomes 
Medical records 
Systematic review 
of the medical 
records: 
Framingham criteria  
Incidence Rates: 
1981 
total: 2.8 per 1000 
person-years 
male: 3.7 
female 2.1 
 
1991 
total: 2.8 per 1000 
person years 
male: 3.4 
female: 2.4 
Using the same diagnostic 
criteria for CHF in 2 
different periods, the 
incidence of CHF in the 
community did not change 
over time 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
Ezekowitz, 2011 
[73] 
Canada 
82,323 
Median age = 75 
years 
Population-based 
study of HF patients 
in a single-payer 
health-care system 
in Alberta, Canada 
from 1999-2007 
Linked databases 
maintained by the 
Ministry of Health 
and Wellness in 
Alberta, Canada: (1) 
the Discharge 
Abstract Database, 
(2) the Ambulatory 
Care Database, (3) 
the Physician 
Claims Database, 
(4) the Alberta 
health Care 
Insurance Registry 
ICD-9 428.x or 
ICD-10 code 150 in 
the primary position 
Incidence by year: 
 
General outpatient 
clinic: 44.7 (1999) 
increased to 50.0 
(2006 
Specialty outpatient 
clinic: 2.5 to 4.4 
ED: 13.0 to 14.7 
Hospital: 39.8 to 
30.9 
 
Incidence rates 
decreased in the 
general outpatient 
clinic and hospital 
over time 
The incidence of heart 
failure is declining over 
time; however the case 
definition is critically 
important when interpreting 
administrative or registry 
data 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
Yeung, 2012 [74] 
Canada 
419,551 
20-105 years 
Population-based 
study of patients in 
Ontario who 
received a diagnosis 
of heart failure 
between 1997-2008 
Linked databases: 
Canadian Institute 
for Health 
Information 
Discharge Abstract 
Database for 
hospital admission 
data and the OHIP 
physician claims 
database for 
ambulatory data 
ICD-9 428.x or 
ICD-10 code 150 
Age and sex 
standardized 
incidence rate of 
heart failure 
decreased 32.7% 
from 454.7 per 
100,000 people to 
306.1 per 100,000 
during the study 
period 
 
Incidence rates 
decreased in the 
outpatient and 
hospital setting 
There was a substantial 
decrease in the incidence of 
heart failure in Ontario, 
suggesting that efforts to 
prevent heart failure over 
the past decade have been at 
least partially successful. 
The greatest decline in 
incidence occurred among 
the oldest cohorts. Ongoing 
vigilance and research is 
required to ensure that 
prevention and treatments 
are optimized for all patients 
at risk of or who have heart 
failure. 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
Blecker, 2014 [130] 
United States 
2,158 ED visits 
≥18 years 
Representative 
sample of annual 
national probability 
sample of 
emergency 
department visits to 
nonfederal, short 
stay hospitals in the 
United States 
National Hospital 
Ambulatory 
Medical Care 
Survey 
(NHAMSCS) 2002-
2010 
ICD-9 402.01, 
402.11, 402.91, 
404.01, 404.03, 
404.11, 404.13, 
404.91, 404.93, and 
428) 
The number of 
emergency 
department visits for 
heart failure 
remained relatively 
stable over the study 
period from 914,739 
in 2002 to 848,634 
in 2010 (annual 
change = -0.7%). .  
Despite the recent trend of a 
reduction in the number of 
acute heart failure 
hospitalizations, the number 
of heart failure ED visits 
remained unchanged. 
Opportunities may exist to 
reduce the substantial 
morbidity and costs related 
to heart failure 
hospitalizations by 
increasing the number of 
patients acutely managed in 
the ED and discharged 
home. 
Hospitalizations 
Chen, 2011 [124] 
United States 
55,097,390 
≥65 years 
From acute care 
hospitals in the 
United States and 
Puerto Rio, fee-for-
service Medicare 
beneficiaries 
hospitalized 
between 1998-2008 
with a principal 
discharge diagnosis 
code for heart 
failure 
National Claims 
History files from 
CMS 
A principal 
discharge diagnosis 
of HF according to 
the following ICD-
9-CM codes: 
402.01, 402.11, 
402.91, 404.01, 
404.11, 404.91, 428, 
404.03, 404.13, and 
404.93 and 428.xx 
 
Unadjusted HF 
hospitalization rate 
decreased from 
2,845 to 1,957 per 
100,000 person-
years (decline of 
31%) 
 
Unique beneficiaries 
at least once for HF 
in a given year 
decreased from 
From 1998-2008, the overall 
risk-adjusted heart failure 
hospitalization rate declined 
among Medicare 
beneficiaries. This decline 
was due to fewer individual 
patients being hospitalized 
with heart failure rather than 
a reduction in the frequency 
of heart failure 
hospitalizations. 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
2,014 to 1,462 per 
100,000 person-
years 
 
Overall risk-
adjusted HF 
hospitalization rate 
decreased from 2845 
to 2007 per 100,000 
person-years 
 
The rate declined in 
2008 compared with 
1998 for white men 
(IRR = 0.73), white 
women (IRR = 
0.72), and black 
women (IRR = 
0.76), black men 
(0.81) 
Black men had the lowest 
rate of decline 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
Croft, 1997 [131] 
United States 
631,306 
≥65 years 
 
Medicare 
beneficiaries with 
Part A, age adjusted 
Medicare 
administrative 
claims 
First hospitalization 
for heart failure 
(ICD-9 428) 
 
Incidence: 
1986 
White: 22.4/1000 
person-years 
Black: 22.4/1000 
person-years 
1993 
White: 24.6/1000 
Black: 26.1/1000 
Between 1986 and 1993 
there were substantial 
increases in initial 
hospitalizations for heart 
failure. The likelihood of 
developing heart failure may 
continue to increase among 
high risk persons as they 
age.  
Jhund, 2009 [99] 
Scotland 
116,556 
Mean age = 71 
years 
 
All patients in 
Scotland 
hospitalized with a 
first episode of heart 
failure between 
1986 and 2003 
National Health 
Service hospitals 
First hospitalization 
for heart failure 
 
Incidence: 
1986 
Men: 1.2/1000 
persons 
Women: 1.3/1000 
persons 
2003 
Men: 1.1/1000 
persons 
Women: 1.0/1000 
persons 
Rates of first hospitalization 
for heart failure continue to 
decrease while survival 
increases. 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
Loehr, 2008 [132] 
United States 
13,995 
45-64 years at 
baseline 
Population based 
cohort study of 
older adults 
Atherosclerosis Risk 
in Communities 
(ARIC) Study 
Hospital discharge 
or death certificate 
with ICD-9 code for 
heart failure (428) 
Incidence: 
White women: 
3.4/1000 person 
years 
White men: 6.0 
Black women: 8.1 
Black men: 9.1 
Increased heart failure 
incidence and case fatality 
in African-Americans 
compared to Caucasians. 
Evidence suggests that racial 
differences in heart failure 
are in large part the result of 
risk factor differences 
Stewart, 2001 [133] 
Scotland 
103,085 
≥55 years 
Scotland (1990-
1996), all ages, not 
adjusted 
Information and 
Statistics Division 
of the National 
Health Service in 
Scotland, Scottish 
Morbidity Record 
Scheme (1990-
1996) 
Hospital discharge 
diagnosis (ICD-9 
428) 
Incidence: 
Women: 1.3-
1.9/1000 persons 
Men: 1.3-2.2/1000 
persons 
Health and hospital services 
need to adapt to an increase 
of incidence that shows no 
sign of abating. 
Curtis, 2008 [89] 
United States 
622,789 
≥65 years 
Medicare 
beneficiaries (65+ 
years, 1994-2003), 
age adjusted 
Medicare 
administrative 
claims 
Hospital discharge 
diagnosis (ICD-9 
428, 402.x1, 
404.x3) and heart 
failure diagnosis 
that appeared on at 
least 3 carrier or 
outpatient claims 
within 20 
consecutive months 
Incidence: 
1994: 32/ 1000 
person-years 
2003: 29/1000 
person-years 
 
Prevalence: 
1994: 9% 
2003: 12% 
Incidence decreased, 
prevalence increased 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
Gustafsson, 2009 
[134] 
Denmark 
4,012 
Mean age = 69 
years 
Outpatients referred 
for HF management 
in 18 Danish HF 
clinics managed 
from 2002-2006 
Electronic patient 
files 
Records on all 
hospital admissions 
were coded 
according to the 
International 
Classification of 
Disease in Denmark 
78% of patients 
were admitted to the 
hospital in the 
period before they 
died 
Ambulatory patients 
referred to a specialized 
heart failure clinic face a 
risk of death or 
hospitalization of about 40% 
after 1 year, hospitalization 
prior to referral to the clinic 
increases likelihood of 
subsequent re-
hospitalization. An 
aggressive strategy to 
prevent readmission or death 
in patients is warranted. 
Gabet, 2015 [125] 
France 
161,131 
Mean age = 78 
years 
Full hospitalizations 
of people living in 
France from 2002-
2012 
French National 
Hospitalization 
Database 
ICD-10 codes I50, 
I11.0, I13.0, I13.2, 
I13.9, J81, K76.1  
161,131 patients 
were hospitalized 
for HF  
 
Crude rate of 
hospitalized heart 
failure was 246.4 
per 100,000 persons, 
increasing with age 
 
Age standardized 
rates were higher in 
men than in women 
for heart failure 
hospitalizations 
Rates of patients 
hospitalized for heart failure 
were almost unchanged 
from 2002-2012. The high 
readmission rates contribute 
to the burden of heart failure 
on the healthcare system 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
 
An annual decrease 
of 1% was observed 
in med from 2002 to 
2010 
Agarwal, 2016 [36] 
United States 
11.5 million 
hospitalizations 
≥55 years 
Derivation sample: 
Community 
surveillance 
component of the 
ARIC study, 
epidemiologic 
surveillance for 
hospitalized ADHF 
 
Application sample: 
Largest publically 
available all-payer 
hospitalization 
database 
Derivation sample = 
Atherosclerosis Risk 
in Communities 
Study 
 
Application sample 
= National Inpatient 
Sample 
 
(1998-2011) 
ADHF (modeled), 
ICD-9 428 primary 
position, ICD-9 
secondary position 
Annual estimates of 
the number of 
ADHF 
hospitalizations 
were about 2X 
higher than those 
based on 428.x 
primary position 
 
ADHF 
hospitalizations 
increased from 
1998-2004 and were 
stable from 2005-
2011 compared to a 
decrease in 428 
primary 
hospitalizations 
There are 1.76 million 
hospitalizations with ADHF 
each year on average 
compared with estimates of 
0.90 million based on ICD-
9-CM code 428 in the 
primary position. Estimates 
of ADHF hospitalizations 
provide a better basis for 
estimating inpatient heart 
failure costs and will be less 
sensitive to the ICD codes 
used to monitor and improve 
patient care. 
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Author, year 
Country 
N= 
Age range (years) 
Study population Data source Definition of Heart Failure Results Conclusion 
Sugrue, 2015 [126] 
Ireland 
51,369 
0-105 years 
Irish, Cross-
sectional, 2002-
2010 (ages 0-105) 
Eurostat database 
ICD10 code for 
heart failure (1-50) 
Age standardized 
hospitalization rates 
decreased from 
157.5 per 100,000 to 
127.2 (decrease of 
19.2%) 
 
Increase in heart 
failure 
hospitalizations for 
those aged 85+ 
years (17.9% to 
26.7%) 
Overall reduction in heart 
failure hospitalizations 
between 2002 and 2010 
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APPENDIX 8: FORMULAS 
Equation 1 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 = 𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻  
Equation 2 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 =  𝐶𝐶𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐𝐴𝐴𝑠𝑠𝐶𝐶 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻
𝐴𝐴𝑠𝑠𝑠𝑠 𝐴𝐴𝑠𝑠𝑐𝑐𝐴𝐴𝑐𝑐𝑒𝑒𝑠𝑠𝐴𝐴 𝑟𝑟𝑎𝑎𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑟𝑟𝑎𝑎𝐴𝐴𝐴𝐴𝑠𝑠  =  𝐴𝐴 + 𝐷𝐷𝐴𝐴 + 𝐵𝐵 + 𝐶𝐶 + 𝐷𝐷 
Equation 3 
𝑆𝑆𝐴𝐴𝐴𝐴𝑠𝑠𝑐𝑐𝐴𝐴𝑐𝑐𝑛𝑛𝑐𝑐𝐴𝐴𝐶𝐶 =  𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻  =  𝐴𝐴𝐴𝐴 + 𝐶𝐶 
Equation 4 
𝑆𝑆𝑟𝑟𝐴𝐴𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝐴𝐴𝐶𝐶 =  𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑎𝑎𝑠𝑠 𝐴𝐴𝑐𝑐𝐴𝐴 ℎ𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴𝐴𝐴 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑤𝑤𝑐𝑐𝐴𝐴ℎ𝑐𝑐𝑜𝑜𝐴𝐴 𝐻𝐻𝐻𝐻  =  𝐷𝐷𝐵𝐵 + 𝐷𝐷 
Equation 5 
𝑃𝑃𝑃𝑃𝑃𝑃 =  𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝐻𝐻𝐻𝐻  =  𝐴𝐴𝐴𝐴 + 𝐵𝐵 
Equation 6 
𝑁𝑁𝑃𝑃𝑃𝑃 =  𝑐𝑐𝑐𝑐𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑎𝑎𝑠𝑠 𝐴𝐴𝑐𝑐𝐴𝐴 ℎ𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴𝐴𝐴 𝐻𝐻𝐻𝐻
𝑎𝑎𝑠𝑠𝑠𝑠 𝑠𝑠𝐴𝐴𝑠𝑠𝑐𝑐 𝐴𝐴𝐴𝐴𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝐴𝐴𝑐𝑐 𝑎𝑎𝑠𝑠 𝐴𝐴𝑐𝑐𝐴𝐴 ℎ𝑎𝑎𝑛𝑛𝑐𝑐𝐴𝐴𝐴𝐴 𝐻𝐻𝐻𝐻  =  𝐷𝐷𝐶𝐶 + 𝐷𝐷 
Equation 7 
𝑃𝑃𝐴𝐴𝐵𝐵𝐴𝐴𝑃𝑃 =  2(𝑟𝑟𝐴𝐴𝑐𝑐𝑟𝑟𝑐𝑐𝐴𝐴𝐴𝐴𝑐𝑐𝑐𝑐𝐴𝐴 𝑐𝑐𝑐𝑐 𝑎𝑎𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴) − 1 = 2( 𝐴𝐴 + 𝐷𝐷
𝐴𝐴 + 𝐵𝐵 + 𝐶𝐶 + 𝐷𝐷) 
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APPENDIX 9: CHAPTER 6 SUPPLEMENTAL TABLES 
Table 15. Trend analysis: Incidence rates for heart failure related ambulatory clinic and emergency 
department visits (ICD-9-CM code 42.8.x), CMS Medicare fee-for-service beneficiaries (2008-2014) 
 Ambulatory Clinic Visits Emergency Department Visits 
 β P for trend β P for trend 
Overall -0.0322 <0.0001 0.0416 <0.0001 
Gender     
Female -0.0428 <0.0001 0.0301 <0.0001 
Male -0.0205 <0.0001 0.0624 <0.0001 
Age (years)     
65-69 -0.0063 0.002 0.0707 <0.0001 
70-74 -0.0495 <0.0001 0.0368 <0.0001 
75-79 -0.0435 <0.0001 0.0371 <0.0001 
80-84 -0.0292 <0.0001 0.0424 <0.0001 
≥85 -0.0162 <0.0001 0.0378 <0.0001 
Race     
White -0.032 <0.0001 0.0402 <0.0001 
Black -0.0124 <0.0001 0.0462 <0.0001 
Hispanic -0.0441 <0.0001 0.0998 <0.0001 
Asian -0.0675 <0.0001 0.0636 <0.0001 
Native 
American -0.0356 0.001 0.0604 <0.0001 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) 
Cochran-Armitage tests for trends were used to estimate trends of heart failure period 
prevalence and incidence over time 
Ambulatory clinic visits included visits to primary care physicians and cardiologists 
Emergency department visits included visits to the emergency department that did not end in a 
hospital admission (routine discharge) and observation stays 
Age recorded on July 1 of a given year 
  
 
 
 
 
  
105 
Table 16. Trend analysis: Period prevalence for heart failure related ambulatory clinic and 
emergency department visits (ICD-9-CM code 42.8.x), CMS Medicare fee-for-service beneficiaries 
(2008-2014) 
 Ambulatory Clinic Visits Emergency Department Visits 
 β P for trend β P for trend 
Overall -0.2810 <0.0001 0.0071 <0.0001 
Gender     
Female -0.0328 <0.0001 0.0037 <0.0001 
Male -0.0249 <0.0001 0.0149 <0.0001 
Age (years)     
65-69 -0.0358 <0.0001 0.0070 <0.0001 
70-74 -0.0338 <0.0001 0.0107 <0.0001 
75-79 -0.0258 <0.0001 0.0141 <0.0001 
80-84 -0.0175 <0.0001 0.0169 <0.0001 
≥85 -0.0105 <0.0001 0.0143 <0.0001 
Race     
White -0.0277 <0.0001 0.0039 <0.0001 
Black -0.0173 <0.0001 0.0289 <0.0001 
Hispanic -0.0261 <0.0001 0.0668 <0.0001 
Asian -0.0391 <0.0001 0.0307 <0.0001 
Native 
American -0.0211 <0.0001 0.0378 <0.0001 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) 
Cochran-Armitage tests for trends were used to estimate trends of heart failure period 
prevalence and incidence over time 
Ambulatory clinic visits included visits to primary care physicians and cardiologists 
Emergency department visits included visits to the emergency department that did not end in a 
hospital admission (routine discharge) and observation stays 
Age recorded on July 1 of a given year 
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Table 17. Incidence rate (per 1,000 person years) for heart failure ambulatory clinic visit a (ICD-9-CM code 428.x), total and by race and 
sex groups, CMS Medicare fee-for-service beneficiaries (2007-2013) 
 Year 
 2008 2009 2010 2011 2012 2013 2014 
 N = 2,288,800 N = 2,319,099 N = 2,383,195 N = 2,496,627 N = 2,644,339 N = 2,952,991 N = 2,811,607 
 % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI 
Total 31.3 31.0 31.5 28.3 28.0 28.5 25.8 25.6 26.0 24.1 23.9 24.3 23.3 23.1 23.5 27.0 26.8 27.1 24.5 24.3 24.7 
Sex                      
Women 29.4 29.1 29.6 26.7 26.4 26.9 24.2 24.0 24.5 22.5 22.3 22.8 21.6 21.4 21.8 24.0 23.7 24.2 22.0 21.7 22.2 
Men 34.8 34.4 35.3 31.2 30.8 31.6 28.6 28.2 29.0 26.7 26.4 27.1 26.2 25.9 26.5 31.7 31.4 32.1 28.6 28.3 28.9 
Age (years)                      
65-69  14.9 14.6 15.2 14.3 14.0 14.6 13.6 13.3 13.9 13.0 12.8 13.3 12.4 12.1 12.7 13.1 12.9 13.4 15.3 15.0 15.6 
70-74  23.8 23.4 24.2 21.7 21.3 22.1 19.8 19.4 20.2 18.0 17.6 18.3 16.8 16.5 17.1 19.2 18.9 19.5 17.0 16.7 17.3 
75-79  32.9 32.3 33.4 29.9 29.4 30.4 27.1 26.6 27.6 24.9 24.5 25.4 24.3 23.8 24.7 27.8 27.3 28.2 23.8 23.4 24.2 
80-84  43.8 43.1 44.5 38.9 38.2 39.6 35.4 34.8 36.0 33.5 32.9 34.2 33.4 32.8 34.0 39.6 39.0 40.2 33.5 32.9 34.1 
≥85  55.2 54.4 56.0 49.0 48.3 49.8 44.8 44.1 45.5 42.8 42.2 43.5 43.1 42.4 43.8 53.0 52.3 53.7 45.0 44.3 45.6 
Race                      
White 31.3 31.0 31.5 28.1 27.9 28.3 25.7 25.4 25.9 23.9 23.7 24.1 23.1 22.9 23.3 27.0 26.8 27.2 24.4 24.2 24.6 
Black 34.4 33.6 35.3 32.0 31.2 32.9 29.3 28.5 30.1 28.3 27.5 29.1 28.3 27.6 29.1 32.6 31.8 33.3 30.3 29.6 31.1 
Hispanic 24.0 22.7 25.3 22.2 21.0 23.4 21.1 20.0 22.3 19.3 18.2 20.4 18.4 17.3 19.5 19.1 18.1 20.2 18.5 17.4 19.7 
Asian 34.6 33.1 36.2 32.4 30.9 34.0 29.3 27.9 30.8 26.6 25.3 28.0 25.5 24.2 26.9 24.1 22.8 25.4 24.0 22.7 25.5 
Native 
American 34.8 31.2 38.8 30.3 27.1 34.0 30.3 27.1 34.0 28.4 25.3 31.8 26.4 23.4 29.6 29.0 26.0 32.4 27.0 24.0 30.4 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
Ambulatory clinic visits included visits to primary care physicians and cardiologists 
Age recorded on July 1 of a given year  
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Table 18. Incidence rate (per 1,000 person years) for heart failure emergency department visit a (ICD-9-CM code 428.x), total and by race 
and sex groups, CMS Medicare fee-for-service beneficiaries (2007-2013) 
 Year 
 2008 2009 2010 2011 2012 2013 2014 
 N = 2,288,818 N = 2,340,599 N = 2,426,043 N = 2,560,615 N = 2,729,579 N = 3,060,200 N = 2,950,865 
 % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI 
Total 9.9 9.8 10.0 10.6 10.5 10.8 10.9 10.8 11.1 11.1 11.0 11.2 11.3 11.2 11.4 12.3 12.2 12.4 13.0 12.9 13.2 
Sex                      
Women 10.4 10.2 10.5 10.9 10.7 11.1 11.3 11.2 11.5 11.3 11.1 11.5 11.3 11.2 11.5 12.2 12.0 12.3 12.7 12.5 12.9 
Men 9.0 8.8 9.3 10.2 10.0 10.4 10.3 10.0 10.5 10.8 10.6 11.0 11.2 11.0 11.4 12.5 12.3 12.7 13.5 13.3 13.8 
Age (years)                      
65-69  4.3 4.1 4.5 4.9 4.7 5.1 5.2 5.0 5.4 5.6 5.4 5.8 5.4 5.3 5.6 5.8 5.6 5.9 7.3 7.1 7.5 
70-74  6.2 6.0 6.5 6.6 6.4 6.9 6.9 6.7 7.1 7.0 6.8 7.2 7.0 6.8 7.2 7.7 7.5 7.9 7.9 7.7 8.1 
75-79  8.9 8.7 9.2 9.7 9.4 10.0 10.0 9.7 10.3 10.1 9.8 10.4 10.4 10.1 10.7 11.3 11.0 11.6 11.3 11.0 11.6 
80-84  13.3 12.9 13.6 14.4 14.0 14.8 14.5 14.1 14.9 14.8 14.4 15.2 15.5 15.1 15.9 17.0 16.6 17.4 17.2 16.8 17.6 
≥85  22.6 22.1 23.1 23.6 23.1 24.1 24.3 23.8 24.8 24.6 24.1 25.1 25.4 24.9 25.9 28.0 27.5 28.5 28.1 27.6 28.6 
Race                      
White 9.8 9.7 10.0 10.6 10.4 10.7 10.8 10.7 11.0 11.1 10.9 11.2 11.2 11.0 11.3 12.1 12.0 12.2 12.9 12.7 13.0 
Black 14.3 13.7 14.9 15.5 15.0 16.2 16.4 15.9 17.1 16.1 15.5 16.7 17.2 16.6 17.8 18.7 18.1 19.2 19.1 18.6 19.7 
Hispanic 2.8 2.4 3.3 3.8 3.3 4.3 4.1 3.6 4.6 4.6 4.1 5.1 4.2 3.8 4.7 5.2 4.7 5.8 5.9 5.3 6.6 
Asian 8.0 7.2 8.8 8.2 7.5 9.0 8.5 7.8 9.3 8.9 8.1 9.7 10.0 9.2 10.9 10.4 9.6 11.3 11.5 10.6 12.5 
Native 
American 13.5 11.4 16.1 15.3 13.1 18.0 13.7 11.6 16.1 12.7 10.7 15.0 15.7 13.5 18.3 18.5 16.1 21.1 19.2 16.8 22.0 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
Emergency department visits included visits to the emergency department that did not end in a hospital admission (routine discharge) and observation stays 
Age recorded on July 1 of a given year 
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Table 19. One year period prevalence of beneficiaries with ≥1 heart failure ambulatory clinic visit a (ICD-9-CM code 428.x), CMS 
Medicare fee-for-service beneficiaries (2007-2013) 
 Year 
 2007 2008 2009 2010 2011 2012 2013 2014 
 N = 2,599,507 N = 2,625,721 N = 2,646,537 N = 2,725,365 N = 2,851,833 N = 3,006,190 N = 3,480,786 N = 3,641,545 
 % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI 
Total 7.6 7.6 7.7 7.4 7.4 7.4 7.3 7.3 7.4 7.2 7.1 7.2 6.9 6.9 7.0 6.7 6.6 6.7 6.4 6.4 6.5 6.3 6.3 6.4 
Sex                         
Women 7.2 7.1 7.2 6.9 6.9 6.9 6.8 6.8 6.9 6.7 6.6 6.7 6.4 6.4 6.5 6.1 6.1 6.2 5.9 5.8 5.9 5.7 5.7 5.7 
Men 8.6 8.5 8.6 8.3 8.3 8.4 8.2 8.2 8.3 8.1 8.0 8.1 7.8 7.7 7.8 7.5 7.5 7.6 7.3 7.3 7.4 7.3 7.2 7.3 
Age (years)                         
65-69  4.3 4.2 4.3 4.1 4.0 4.1 4.1 4.0 4.1 4.0 4.0 4.1 3.9 3.8 3.9 3.7 3.6 3.7 3.4 3.4 3.5 3.3 3.3 3.4 
70-74  5.9 5.8 5.9 5.7 5.6 5.8 5.5 5.5 5.6 5.4 5.4 5.5 5.2 5.2 5.3 5.0 4.9 5.0 4.8 4.7 4.8 4.7 4.7 4.7 
75-79  7.8 7.8 7.9 7.6 7.5 7.7 7.6 7.5 7.7 7.4 7.4 7.5 7.1 7.1 7.2 6.9 6.8 7.0 6.7 6.6 6.7 6.6 6.6 6.7 
80-84  10.1 10.0 
10.
2 9.8 9.7 9.9 9.8 9.7 9.9 9.6 9.5 9.7 9.4 9.3 9.5 9.1 9.0 9.2 9.0 8.9 9.1 9.0 8.9 9.0 
≥85  12.3 12.2 
12.
4 
12.
0 
11.
9 
12.
1 12.0 
11.
9 
12.
1 
11.
8 
11.
7 
11.
9 
11.
6 
11.
5 
11.
7 
11.
4 
11.
3 
11.
5 
11.
5 
11.
4 
11.
5 
11.
5 11.4 
11.
5 
Race                         
White 7.5 7.5 7.6 7.3 7.3 7.4 7.2 7.2 7.3 7.1 7.0 7.1 6.8 6.8 6.9 6.6 6.5 6.6 6.4 6.3 6.4 6.3 6.2 6.3 
Black 8.9 8.7 9.0 8.7 8.6 8.9 8.8 8.7 8.9 8.7 8.5 8.8 8.6 8.5 8.8 8.3 8.2 8.5 7.9 7.8 8.0 8.0 7.9 8.1 
Hispanic 6.2 6.1 6.4 5.8 5.6 6.0 5.8 5.6 5.9 5.6 5.4 5.7 5.5 5.4 5.7 5.4 5.2 5.6 5.2 5.1 5.4 5.1 4.9 5.2 
Asian 8.6 8.4 8.8 8.2 8.0 8.4 8.3 8.1 8.5 8.1 7.9 8.3 7.6 7.4 7.8 7.3 7.2 7.5 6.8 6.6 6.9 6.5 6.3 6.6 
Native 
American 8.4 7.9 8.9 8.0 7.5 8.5 8.1 7.6 8.6 8.0 7.5 8.5 7.6 7.1 8.1 7.4 6.9 7.8 7.5 7.1 8.0 7.1 6.7 7.6 
Abbreviations: International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
Ambulatory clinic visits included visits to primary care physicians and cardiologists 
Age recorded on July 1 of a given year 
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Table 20. One year period prevalence of beneficiaries with ≥1 heart failure emergency department visit (ICD-9-CM code 428.x), CMS 
Medicare fee-for-service beneficiaries (2007-2013) 
 Year 
 2007 2008 2009 2010 2011 2012 2013 2014 
 N = 2,599,507 N = 2,625,721 N = 2,646,537 N = 2,725,365 N = 2,851,833 N = 3,006,190 N = 3,480,786 N = 3,641,545 
 % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI 
Total 2.0 2.0 2.0 2.0 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.1 2.2 2.1 2.1 2.1 2.1 2.1 2.2 
Sex                         
Women 1.9 1.9 1.9 1.9 1.9 1.9 2.0 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.0 2.1 2.0 2.0 2.1 2.1 2.1 2.1 
Men 2.1 2.1 2.1 2.1 2.1 2.2 2.2 2.2 2.2 2.2 2.2 2.3 2.2 2.2 2.3 2.2 2.2 2.2 2.1 2.1 2.2 2.2 2.1 2.2 
Age (years)                         
65-69  1.0 1.0 1.1 1.1 1.0 1.1 1.1 1.1 1.1 1.2 1.1 1.2 1.2 1.2 1.2 1.1 1.1 1.2 1.1 1.1 1.1 1.1 1.1 1.1 
70-74  1.4 1.3 1.4 1.4 1.4 1.4 1.4 1.4 1.5 1.5 1.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.4 1.4 1.5 1.5 1.5 1.5 
75-79  1.8 1.8 1.9 1.9 1.9 1.9 1.9 1.9 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.0 2.1 2.0 2.0 2.0 2.1 2.0 2.1 
80-84  2.6 2.5 2.6 2.6 2.5 2.6 2.7 2.7 2.7 2.8 2.7 2.8 2.8 2.7 2.8 2.8 2.8 2.9 2.8 2.7 2.8 2.9 2.9 3.0 
≥85  3.9 3.8 4.0 4.0 3.9 4.1 4.1 4.0 4.1 4.2 4.1 4.2 4.2 4.2 4.3 4.3 4.2 4.3 4.3 4.2 4.3 4.4 4.3 4.4 
Race                         
White 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.1 2.1 2.1 2.1 
Black 2.9 2.8 3.0 3.0 2.9 3.1 3.3 3.2 3.3 3.5 3.4 3.6 3.6 3.5 3.7 3.6 3.5 3.7 3.5 3.4 3.6 3.6 3.5 3.7 
Hispanic 2.0 2.0 2.0 2.0 2.0 2.0 2.1 2.0 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.1 2.0 2.0 2.1 2.1 2.1 2.1 
Asian 2.9 2.8 3.0 3.0 2.9 3.1 3.3 3.2 3.3 3.5 3.4 3.6 3.6 3.5 3.7 3.6 3.5 3.7 3.5 3.4 3.6 3.6 3.5 3.7 
Native 
American 0.7 0.6 0.7 0.6 0.6 0.7 0.7 0.6 0.7 0.8 0.7 0.8 0.8 0.8 0.9 0.8 0.7 0.8 0.9 0.8 1.0 1.0 0.9 1.0 
Abbreviations: Confidence interval (CI) 
Emergency department visits included visits to the emergency department that did not end in a hospital admission (routine discharge) and observation stays 
Age recorded on July 1 of a given year 
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